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The transmembrane glycoprotein MUC1 is aberrantly expressed in the majority 
of pancreatic ductal adenocarcinoma cases and promotes tumor progression by 
engaging in morphogenetic signaling through its cytoplasmic tail.  Furthermore, MUC1 
can translocate to the nucleus and function as a transcriptional co-regulator in 
conjunction with transcriptional complexes containing activator protein-1 (AP-1) and p53.  
The specificity of these interactions are thought to rely on specific patterning of post-
translational modifications within the cytoplasmic tail of MUC1.  
Within this dissertation, we examined how MUC1 influences the formation and 
activity of these transcription factors and the resulting impact on tumor progression and 
metastasis.  In our first set of studies, we evaluated the global pattern of post-
translational modifications present within MUC1.  While previous studies have shown 
phosphorylation of specific residues, we found that MUC1 exists in a 
hyperphosphorylated state containing potentially more than 10 phosphorylated residues.  
Furthermore, malignant tumors exhibit a higher degree of phosphorylation and changes 
in the environment also drive changes in this patterning.  This is also true of several 
MUC1 splice variants, suggesting that MUC1 can readily integrate numerous signaling 
pathways to initiate the appropriate signaling compartment.   
We further evaluated how MUC1 expression regulates the function of AP-1 and 
found that MUC1 promoted the formation of AP-1 dimers consisting of c-Jun and FRA-1.  
We further demonstrated that FRA-1 is a novel driver of pancreatic tumor migration, 
invasion, and overall progression both in conjunction, and independent of MUC1 
expression.  In vivo studies show increased expression of FRA-1 in pancreatic cancer 
and increased expression of FRA-1 target genes involved in epithelial-to-mesenchymal 
transition suggesting FRA-1 may be a potential therapeutic target in pancreatic cancer. 
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We explored this possibility utilizing inhibitors of bromodomain and extraterminal 
domain containing proteins, which had shown inhibitory effects on expression of FRA-1.  
We found we were unable to reproduce these effects, however, combining FRA-1 
knockdown with BET inhibition resulted in additive effects in decreasing cellular growth.  
These effects are seemingly due to diminished expression of pro-growth and survival 
genes.  Future studies targeting FRA-1 may identify better therapeutic partners. 
Lastly, we examined how the mutational status of p53 influenced its interaction 
with MUC1.  As mutant p53 has been shown to exhibit gain-of-function effects in cancer, 
we sought to evaluate whether different mutants would preferentially interact with MUC1 
and any potential transcriptional changes that result.  We found that MUC1 preferentially 
interacted with the hotspot mutant R273H, as compared to R175H and wildtype p53 in a 
dox-inducible model.   
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1. Pancreatic Cancer 
1.1 Diagnosis, Prognosis and Treatment 
	
 Pancreatic cancer is currently the fourth-leading cause of cancer related deaths 
within the United States [1, 2].  This is projected to rise to the second-leading cause of 
cancer-related death by 2020 [3].  Despite extensive research focused on therapeutic 
treatment of cancer, the prognosis for patients diagnosed with pancreatic cancer 
remains poor, even as survival for other cancers have shown marked improvements.  
Furthermore, the majority of pancreatic cancer cases are the aggressive pancreatic 
ductal adenocarcinoma (PDAC), as opposed to the less malignant neuroendocrine 
tumors[4]. The current five-year survival rate for pancreatic cancer is approximately 6% 
and has remained largely unchanged for decades[2].  Surgical resection of the pancreas 
is the best option for patient survival, and patients that have undergone the Whipple 
procedure have a five-year survival rate near 20%[2, 5, 6].  However, due to the location 
of the tumor, non-specific symptoms at presentation, and propensity for distal 
metastases at diagnosis, only a fraction of patients are eligible for the procedure.  
Studies for early biomarkers of pancreatic cancer are currently ongoing, however, have 
not yet made a significant impact on the diagnosis of PDAC.  
Over the past two decades the standard treatment of pancreatic cancer has 
largely consisted of the deoxycytidine analogue gemcitabine either alone, or in 
conjunction with other chemotherapeutic drugs, most recently Abraxane™ [7, 8].  The 
multidrug combination FOLFIRINOX has shown potential for extension of patient 
survival, however, the regimen is associated with significant toxicity [7, 9].  Ultimately 
none of the current standard therapies for pancreatic cancer provide curative benefit to 
patients, as the disease often resists treatment, either through intrinsic or adaptive 
mechanisms [10].  The molecular mechanisms involved in the formation and progression 
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of pancreatic cancer must be elucidated to identify novel therapeutic targets and improve 
the outcome of patients. 
 
1.2 Genetics and Development 
	
 PDAC develops through the accumulation of genetic alterations that confer a 
selective advantage upon the cells.  While the majority of pancreatic cancer cases are 
ductal adenocarcinoma, the precise cell of origin remains debated.  As the ductal cells 
represent a minor fraction of the pancreas, it is hypothesized that acinar-to-ductal 
metaplasia (ADM) plays a major role in the development of pancreatic cancer [11].  As 
mutations accumulate, the normal epithelia of the pancreas undergo transition to 
pancreatic intraepithelial neoplasias (PanINs), eventually developing into invasive 
adenocarcinoma [12].  This transition is well defined, as cells progress from PanIN-1 
through PanIN-3 with increasing dysplasia before ultimately becoming invasive disease 
(Figure 1.1).  The histology of pancreatic cancer is characterized by robust stromal 
involvement and desmoplasia with the actual cancer cells representing a minor fraction 
of the tumor (Figure 1.2).  This stromal reaction has significant impact on the treatment 
of PDAC as it creates a cellular, molecular, and physical barrier for drug delivery and 
entry of effector lymphocytes and other immune cell types.  
There are four major genetic alterations that commonly occur within pancreatic 
cancer [13].  More than 90% of pancreatic cancers exhibit activating mutations within the 
Kras oncogene and 50-75% of tumors exhibit alterations in the tumor suppressor p53 
[14].  These two alterations are sufficient to induce spontaneous pancreatic tumor 
development when engineered for pancreas cell specific expression in mice and provide 
the basis for the KPC mouse model of spontaneous pancreatic cancer [15].  In addition 
to these two drivers, loss of the CDKN2A locus and SMAD4 are also extremely common 
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[13]. Beyond the four common mutations, pancreatic cancer harbors patient specific 
mutations within a number of alternative pathways promoting oncogenic signaling 
through several distinct networks.  As a result, pancreatic cancer represents a diverse 
malignancy that is proposed to consist of distinct molecular subtypes [16-18].  Most 
recently, it has been proposed that PDAC consists of four distinct subtypes based on 
combined genomic, epigenomic, and transcriptomic analyses, however, the conclusions 
from these studies remain controversial as tumors are often complicated by 
contamination by stromal cells [18]. Each of these subtypes appears to utilize different 
signaling pathways for growth and progression.  Interestingly, expression of different 
mucin glycoproteins correlates with different subtypes of pancreatic cancer.   
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Figure 1.1:  Development of Pancreatic Ductal Adenocarcinoma 
The progression of events involved in the development of pancreatic ductal 
adenocarcinoma is well defined[12].  During development, lesions progress through a 
number of well-characterized stages (PanIN-1 through 3) before finally progressing to 
invasive carcinoma.  Among the earliest events is the mutation of Kras, typically at 
hotspot residues 12 and 13.  Other well-characterized events included loss of tumor 
suppressors such as p16, p53, and SMAD4.  
  













Figure 1.2:  Histology of Pancreatic Ductal Adenocarcinoma 
Images representing either normal pancreas (A) or pancreatic ductal adenocarcinoma 
(B) are presented.  Slides were counterstained with hematoxylin and scanned at 40X 
magnification using the Ventana Coreo slide scanner in the UNMC Tissue Sciences 
Core. Normal pancreas consists of both an exocrine and endocrine compartment.  The 
exocrine function primarily consists of acinar cells, with a minor fraction of ductal cells, 
and cells within the Islet of Langerhans control the endocrine function.  In comparison, 
pancreatic ductal adenocarcinoma exhibits an intense stromal reaction and in many 
tumors the proportion of stroma exceeds that of the tumor cells.   
  
Normal Pancreas Pancreatic Ductal Adenocarcinoma
Figure 1.2
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2.  Mucins 
2.1. Structure and Function 
	
 Mucins comprise a large family of glycoproteins expressed by a variety epithelia; 
including the respiratory, gastrointestinal, and reproductive tracts [19].  These high 
molecular weight glycoproteins are classified as either secretory mucins, which are 
secreted into the extracellular space, or membrane bound mucins that contain a 
transmembrane domain and are inserted into the apical surface of epithelial cells [19, 
20].  Together these mucins make up a significant proportion of the proteins found in the 
mucosal layers that coat the epithelial surface at the air to cell interface [20-23].  The 
secretory family of mucins includes MUC2, MUC5AC, MUC5B, MUC6, and MUC7, 
whereas, MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, 
and MUC20 are all membrane bound [20].  Under normal physiological conditions, 
mucins play an essential role in lubrication, chemical sensing, and organization of the 
local microenvironment surrounding the cells [19].  Mucins also form a protective barrier 
to pathogens and are postulated to act as sensors of the surrounding environmental 
conditions [24-26].  Transmembrane mucins can propagate extracellular signals into the 
cells through phosphorylation of specific residues in the cytoplasmic tail, allowing cells to 
adapt to the surrounding environment [26].   
 A defining structural characteristic of mucin proteins is the presence of a tandem 
repeat domain or mucin domain [20]. The amino acid sequence and number of these 
repeats varies from mucin to mucin and are rich in serine, threonine, and proline 
residues resulting in the presence of many potential sites of O-linked glycosylation [27, 
28].  The presence of O-glycosylation is critical for mucin function, as these 
oligosaccharides are involved in ligand-receptor interactions and mediate the gel-forming 
properties critical for organization of the extracellular environment [29, 30].   As the 
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number of these repeats is highly variable, individual mucins can contain a wide array of 
potential glycosylation patterns [20] (Figure 1.3).   
The process by which mucin type O-linked glycosylation occurs is well 
characterized [31-34] (Figure 1.4).  The initiating step involves the addition of N-acetyl-
Galactosamine (GalNAc) to serine or threonine residues present in the mucin backbone 
to form the Tn-epitope and is catalyzed by a large family of enzymes called GalNAc-
transferases (GalNAc-Ts) [31, 35].  These structures can then be further extended to 
form Core 1, 2, 3, or 4 structures based on the identity and linkage of the carbohydrate 
moiety [36]. Core 1 structures are formed by addition of Galactose (Gal) in a β1-3 
linkage to GalNAc.  In contrast to the diversity of GalNAc-Ts, a singular enzyme, Core 1 
Gal-transferase, catalyzes this addition [37].  Core 1 structures can then be extended or 
Core 2 structures can be generated by addition of GlcNAc in a β1-6 linkage to the 
existing GalNAc of the Core 1 structure by C2GnTs [38-40].  As an alternative to Core 1, 
Core 3 structures can be generated through addition of GlcNAc in a β1-3 linkage to the 
Tn epitope [41].  Like Core 1 structures, Core 3 structures may be extended or act as the 
scaffold for Core 4 structure generation through addition of another GlcNAc in a β1-6 
linkage [40].  While other core structures do exist, Core 1, 2, 3, and 4 structures 
comprise the primary glycan structures observed with the human body. 
 
2.2 Deregulation of mucin expression and O-glycosylation in Cancer 
	
Deregulated expression of mucins is observed in many malignancies, particularly 
within adenocarcinomas (Table 1.1).  Elevated expression of MUC1 is common in 
pancreatic, breast, colon, lung, and prostate cancer [42-45]. Expression of MUC1 
appears to be a major factor in the progression of pancreatic cancer, as knockout of 
MUC1 results in significantly prolonged survival in the KPC mouse model of pancreatic 
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cancer (Figure 1.5).  This effect is presumably through the oncogenic signaling capacity 
of the MUC1 cytoplasmic tail.  Similarly, knockout of MUC1 expression in a mouse 
model of mammary tumors also delayed tumor progression [46]. MUC4 expression is 
increased in colon adenocarcinoma samples and is a proposed marker of aggressive 
pancreatic cancer [42, 47].  Elevation of the MUC16 marker (CA125) is well studied in 
ovarian cancer, however, more recently expression of MUC16 has been implicated as a 
significant factor in the progression of pancreatic cancer[48-51].   
Additionally, many tumors exhibit increased expression of truncated or aberrant 
O-glycans.   These alterations in tumor glycobiology primarily occur through 2 
mechanisms; Neo-synthesis or incomplete synthesis [52].  In particular, the expression 
of Core 1 based structures, such as T, Tn, or sialyl-Tn(STn), are observed in a majority 
human carcinomas, whereas in healthy tissues, these structures are typically absent [42, 
53, 54].  Increased expression of other glycoepitopes, such as sialyl-Lewisx/a, are also 
commonly observed [55].  In contrast, decreased expression of Core 3 and 4 structures 
are observed in gastric and colorectal cancers [56, 57].  In many instances, expression 
of these structures is driven by alterations in the expression of enzymes involved in the 
glycosylation process.  For example, the extension of Core 1 structures relies on a single 
enzyme, C1GalT1.  This enzyme requires a specific chaperone, COSMC, for proper 
folding and functional activity [58-60].  Cells lacking expression of COSMC have been 
shown to express increased levels of Tn and STn epitopes [61, 62].  Furthermore, a 
significant percentage of cancers exhibit hypermethylation of the COSMC gene, 
resulting in decreased expression of C1GalT1 and increased formation of Tn and STn 
epitopes [63].  Deregulation of other enzymes involved in O-linked glycosylation has 
been observed in a variety of cancers [55, 64-68]. 
Expression of these aberrant glycoforms is often used as a diagnostic or 
prognostic marker of tumor progression.  CA19-9 detects the presence of sialyl lewisa on 
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mucin core proteins[69, 70].  Other markers include DuPan-2, Span-1, CA50, CA242, 
CA195, CAM43, and SSEA[70-72].  All of these markers are mucin type 
oligosaccharides.  While the levels of these markers are commonly monitored 
throughout tumor progression the sensitivity and specificity of these assays as 
diagnostic tools is relatively poor.  As such, use of these assays has not proven useful 
for early diagnosis of pancreatic cancer. 
Phenotypically, expression of aberrant O-glycans has been correlated with 
increased aggressiveness and metastatic behavior in a variety of cancers [53, 55, 63].  
These effects are hypothesized to be the result of altered interactions between tumor 
cells and binding partners in the extracellular environment, such as selectins and 
integrins [55].  However, these alterations may result in perturbations to the signaling of 
mucin cytoplasmic tails leading to potentiation of oncogenic signals.   Re-expression of 
enzymes involved in the extension of the carbohydrate chain, such as Core 3 synthase, 
results in a decrease in these aggressive properties in pancreatic cancer cells by 
influencing these interactions suggesting that targeting the glycosylation process may be 
a viable strategy in cancer [73].   
 
2.3 MUC1:  Signaling Through the Cytoplasmic Tail 
	
 MUC1 is the best-characterized transmembrane mucin for its signaling role within 
tumorigenesis; however, both MUC4 and MUC16 have also been shown to signal 
through their cytoplasmic tails [74, 75].  MUC1 is a type I transmembrane protein that 
exists as a heterodimer at the apical cell surface.  The formation of the dimer is through 
an autoproteolytic cleavage event that occurs during translation of MUC1 at the SEA 
(sea urchin sperm protein, enterokinase, agrin) domain [19, 20, 76].  The resulting two 
subunits then associate in a strong, non-covalent interaction. The protein undergoes 
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extensive glycosylation, both O-linked and N-linked, before insertion into the plasma 
membrane [19, 20](Figure 1.6).  The N-terminus of MUC1 consists of a heavily O-
glycosylated extracellular portion that extends from the cell surface and plays a role in 
organization of the glycocalyx [20].  The C-terminus of MUC1 (MUC1.CT) consists of a 
short extracellular domain, a transmembrane domain, and a 72 amino acid cytoplasmic 
tail.  
In response to perturbations of the extracellular environment, binding of ligand 
molecules, or interaction with receptor tyrosine kinases (RTKs), MUC1 can become 
phosphorylated at specific residues within the cytoplasmic tail [26, 77-79].  Under normal 
physiological conditions, MUC1 is spatially separated from RTKs that are expressed on 
the basal surface.  Loss of polarity, either through mechanical injury of the epithelia or as 
a result of cellular transformation, allows MUC1 to interact with these partners and drive 
downstream signaling (Figure 1.7)[26].  As the cytoplasmic tail of MUC1 contains 22 
potential sites of phosphorylation, it is possible to integrate a wide range of signals 
through specific phosphorylation patterns.  This combinatorial pattern of phosphorylation 
is likely critical for the specificity of interactions of the cytoplasmic tail with a host of 
effectors [77, 80-82] (Figure 1.8).  
As a result of all these potential interaction partners, the propagation of signals 
through the cytoplasmic tail is extremely complex (Figure 1.9).  Interaction of MUC1 with 
receptor tyrosine kinases can result in the activation of a number of downstream 
cascades.  Phosphorylation of the MUC1 cytoplasmic tail has been shown to increase 
the interaction of MUC1 with Grb2 to drive downstream activation of ERK [81, 83].  
MUC1 also promotes signaling through the PI3K/Akt signaling pathway to drive anti-
apoptotic signaling [84, 85]. MUC1 also interacts with all four members of the ErbB 
family of receptor tyrosine kinases [86].  Other studies have shown that MUC1 is 
capable of initiating signaling through JNK to drive migration and invasion in 
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hepatocellular carcinoma[87, 88].  Induction of these signaling cascades results in 
eventual activation of transcriptional effectors, such as NF-κB and C/EBP, to alter the 
expression of genes critical in tumor progression and survival[81, 85, 89]. 
These interactions can also result in alterations to localization of signaling 
complexes.  The interaction of MUC1 with the EGFR receptor results in not only 
phosphorylation of MUC1, but also in nuclear localization of EGFR [79].  How MUC1 
translocates to the nucleus remains unknown, however, it may depend on endosomal 
internalization, similar to the mechanism of nuclear localization of ErbB2 [90]. Supporting 
this idea is the evidence that both MUC1 and EGFR can associate with CIN85, which 
regulates internalization of EGFR [91, 92].  Furthermore, the presence of specific 
tyrosine residues in the cytoplasmic tail is critical for clathrin-mediated endocytosis of 
MUC1, suggesting that phosphorylation of MUC1 may be a critical determinant in the 
localization of signaling complexes [93]. 
MUC1 expression also has significant impact on the surrounding tumor 
microenvironment through interactions with the surrounding stroma and tumor 
associated cells.  Expression of select carbohydrate epitopes on MUC1 has been shown 
to promote the invasion of pancreatic cancer cells into the surrounding vascular [94].  As 
a result, MUC1 regulates the adhesive and anti-adhesive balance within the tumor.  
MUC1 has also been shown to play an immunomodulatory role through interactions with 
specific immune effector cells [95-97].  While these interactions are thought to be 
primarily immunosuppressive, the presence of anti-MUC1 autoantibodies within tumor 
patients suggests that MUC1 may be a viable target for immunotherapies [98, 99].   
Specific studies have also demonstrated the capacity of MUC1.CT to interact 
with the transcription factors p53 and c-Jun [77, 80, 100].  The interaction of MUC1.CT 
with transcription factors is proposed to result in the translocation of MUC1 to the 
nucleus where it acts as a transcriptional co-regulator. The interaction of MUC1 and p53 
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has been shown to promote survival based signaling by promoting expression of p21, 
while inhibiting expression of the pro-apoptotic protein Bax [80]. This suggests that 
MUC1 may promote tumor cell survival by altering the normal function of p53 or by 
promoting gain-of-function effects with mutant p53. While MUC1 has no DNA binding 
capacity, it is found in complex with p53 at these promoter elements suggesting that 
MUC1 can modulate the formation of transcriptional complexes.   Additional studies 
have shown that this interaction requires phosphorylation of specific motifs within the 
cytoplasmic tail [77].  These studies have also demonstrated that these complexes 
appear to impact the expression of connective tissue growth factor (CTGF) and matrix 
metalloprotease 1 (MMP1) through the binding of upstream promoter elements [77, 100].  
This binding is accompanied by the apparent loss of the proto-oncogene, c-Jun, from the 
same promoter element. How the mutational status of p53 influences the interaction with 
MUC1.CT and the resulting impact on gene expression is unknown. 
MUC1 has also been shown to associate with β-catenin through a serine rich 
motif present in the cytoplasmic tail [101, 102].  This motif is similar to the serine rich 
motif of APC that allows for interaction with β-catenin.  Like the association with p53, this 
interaction has shown to promote translocation of MUC1 to the nucleus and alter the 
regulation of Wnt target genes [103].  This interaction is modulated by phosphorylation of 
specific residues in the cytoplasmic tail.  Phosphorylation of a serine residue near the 
serine rich motif by GSK3β decreases the affinity of this interaction, whereas 
phosphorylation of tyrosine residues by c-Src appears to increase the affinity of MUC1 
for β-catenin [104, 105].  These interactions may also influence the balance of adhesive 
properties by changing the localization of β-catenin from junctional complexes. 
Translocation of MUC1 to the mitochondrial membrane has also been observed 
in select circumstances [106].  In these studies, MUC1 was shown to inhibit pore 
formation by interfering with Bax oligomerization.  This binding requires the CQC motif 
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present within the cytoplasmic tail of MUC1.  This association results in inhibition of 
cytochrome C release and blocking of the apoptotic pathway.   The translocation of 
MUC1 to the mitochondria appears to rely on the association with the molecular 
chaperone Hsp90 [107].  Interestingly, expression of MUC1 has also been shown to 
promote FasL induced apoptosis suggesting MUC1 may balance several apoptotic 
pathways [108].  Supporting this idea is the evidence that MUC1 expression is often 
induced in response to cellular stressors, such as presence of reactive oxygen species 
(ROS) [109]. 
As a result of all these interactions, MUC1 acts as a signaling hub for an 
extremely complex network of pathways.  How MUC1 integrates all these pathways to 
initiate the correct downstream effect remains unknown.  Furthermore, how MUC1 
exerts its transcriptional co-regulatory role is still not fully understood.  MUC1 appears to 
alter the formation of transcriptional machinery, however, whether these complexes are 
altered through direct association with MUC1 or through indirect alterations to upstream 
signaling cascades is unknown.  Therefore further study of the molecular mechanisms 
involved in mucin signaling is needed. 
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Table 1.1:  Deregulation of Mucin Expression in Cancer 
Table list mucins for which expression is altered in different cancers.  References are 






Deregulation of Mucin expression in Cancer 
Mucin Cancer Reference 




Remmers, et al[53] 
Hinoda, et al[110] 
Huang, et al[111] 
Haridas, et al[51] 
Higashi, et al[50] 
MUC1, MUC2, MUC3, 
MUC4, MUC5AC, MUC5B, 
MUC6 
Breast Cancer 
Ghosh, et al[112] 
Rakha, et al[113] 
Mukhopadhyay, et al[114] 
MUC1, MUC2, MUC4, 
MUC5AC, MUC5B, MUC6, 
MUC17 
Colon Cancer Terada, et al[115] Krishn, et al[42] 
MUC1, MUC2, MUC4, 
MUC5AC, MUC6 Lung Cancer 
Awaya, et al[44] 
Kwon, et al[116] 
MUC1, MUC4, MUC16 Ovarian Cancer Yin, et al[117] Chauhan, et al[118] 
MUC1, MUC2, MUC4 Prostate Cancer Singh, et al[45] Osunkoya, et al[119] 
MUC1, MUC2, MUC3, 
MUC4, MUC5AC, MUC5B, 
MUC6, MUC13 




Figure 1.3:  Structural Organization of MUC1, MUC4, and MUC16 
Schematic representing the domain organization of the mucins: MUC1, MUC4, and 
MUC16.  Structures are not drawn to scale.  These mucins contain cleavage sites 
(highlighted by dashed line) and exist at the cell surface as a dimer.  In addition to the 
common mucin repeat domain, each mucin contains regions of unique sequences 
conferring specific functions.  The sequence of the cytoplasmic tails is presented with 

































Figure 1.4:  Mucin Type O-Glycosylation 
Schematic representing the addition of carbohydrates involved in mucin type O-
glycosylation.  Initiation involves addition of GalNAc to serine or threonine residues 
present in the mucin backbone to form the Tn epitope.  These structures can be further 
extended into Core 1,2,3, or 4 structures depending on the identity of the carbohydrate.  
In cancer, the formation of truncated glycans (highlighted in red box) is common due to 


















GalNAc Gal NeuAc GlcNAc
Figure 1.4
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Figure 1.5:  Loss of MUC1 Extends KPC Survival 
MUC1 wildtype and KO KPC mice were generated by crossing the standard MUC1 KO 
mouse into the KPC mouse model of pancreatic cancer.  Survival was tracked over time 
and a Kaplan-Meier plot showing survival of KPC mice that are either wildtype for MUC1 
expression or have MUC1 knocked-out was generated based upon the survival data.  
Death from cancer was confirmed by necropsy.  Statistics were performed using 2-way 
ANOVA. 
  



















Figure 1.6:  Processing of MUC1 
Following translation, MUC1 undergoes an autoproteolytic cleavage at its SEA domain.  
These two subunits are associated through a strong, non-covalent interaction.  MUC1 
then undergoes further processing in the Golgi with the attachment of carbohydrates in 
an O- (Serine/Threonine) and N-linked (Asparagine) fashion.  MUC1 is then inserted into 




O- and N-linked glycosylation
of extracellular domain





Figure 1.7:  Model of MUC1 Activation in Response to Loss of Polarity 
Figured based upon hypotheses presented in Singh, et al[26].  Under normal 
physiological conditions MUC1 and receptor tyrosine kinases (RTKs) are spatially 
separated.  However, with loss of normal junctional complexes through mechanical 
injury or loss of polarity due to malignant transformation, MUC1 and RTKs can associate 









Figure 1.8:  Known Interaction Partners of the MUC1 Cytoplasmic Tail 
A schematic of the MUC1 cytoplasmic tail and known regions involved in the association 
with signaling partners.  Phosphorylation sites with known kinases are highlighted in red 
text.  Additional interaction partners are also shown below.  These additional partners do 


























Figure 1.9:  Model of MUC1 Signaling in Cancer 
MUC1 has been shown to initiate pro-oncogenic effects through a number of distinct 
mechanisms.  1) MUC1 can interact with RTKs (or other kinases) resulting in 
phosphorylation of the cytoplasmic tail.  2) MUC1 can as a chemical sensor of the 
surrounding environment and sequester various factors from the extracellular 
environment. 3) MUC1 can interact with and organize the surrounding 
microenvironment.  4) MUC1 propagates signals through a number of downstream 
effector pathways.  5) MUC1 can regulate the compartment of signaling in association 
with other factors.  6) MUC1 can translocate to the nucleus in association with 
transcription factors to alter gene expression.  7) Translocation of MUC1 to the 


















3.  AP-1 
3.1 Structure and Function 
	
Activator Protein-1 (AP-1) is a dimeric transcription factor canonically consisting 
of either a homodimer of Jun proteins or a heterodimer of Jun and Fos proteins [121].  
The initial discovery and characterization of this factor demonstrated significant affinity 
for a common cis-element in the promoters of genes regulated by addition of phorbol 
esters, such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) [122, 123].  These 
promoter elements were termed TPA-response elements (TREs) and are among the 
best-defined sites of AP-1 binding [123].  The consensus sequence for the TRE is 
TGAC/GTCA.  Interestingly, the individual components of AP-1 were discovered as viral 
oncogenes prior to the identification of the cellular homologs.  V-Jun was discovered in 
the viral genome of avian sarcoma virus, whereas v-Fos was discovered within the 
genome of FBJ-murine osteosarcoma virus [124, 125].  Subsequent studies discovered 
the cellular homologs, c-Jun and c-Fos, which constitute mammalian AP-1. 
Within humans there are 3 distinct JUN family members (c-Jun, JunB, and JunD) 
and 4 FOS family members (c-Fos, FosB, FRA-1, and FRA-2) [121, 126].  These 
proteins are part of a larger class of proteins called Bzip proteins that contain a basic 
region that facilitates the binding of DNA, and a leucine zipper for dimerization.  A high 
degree of similarity exists across family members, particularly within the Bzip domain 
suggesting potential functional redundancy to a degree (Figure 1.10).  Typically, 
functional dimerization of AP-1 proteins is dependent on phosphorylation of residues that 
stabilize the proteins.  Phosphorylation of the delta domain in c-Jun is critical for 
regulation of its stability and is absent in the viral homolog v-Jun [127].  Phosphorylation 
of serines 63 and 73 within this domain, results in stabilization of the protein, and 
functional activity [128, 129].  However, it also creates binding sites for regulatory 
proteins that turn off the transcriptional signals by degrading c-Jun [130].  Similarly, the 
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stability of c-Fos and FRA-1 is regulated by the presence of a C-terminal degradation 
sequence [131, 132].  Like v-Jun, v-Fos lacks this domain and as a result is significantly 
more stable than its normal cellular counterpart [133].  Similarly, truncated ΔFosB that 
lacks the C-terminal degradation sequence also exhibits prolonged stability 
demonstrating that these sequences are critical for the regulation of Fos family proteins 
[134].  Phosphorylation of residues near the basic region has also been shown to 
regulate DNA binding of AP-1 proteins, presumably by altering the net positive charge 
required to associate with DNA [135]. 
 
3.2 Roles of Jun and Fos in Normal Development 
	
 The role of Jun and Fos proteins in normal developmental processes has been 
well studied through the generation of specific knockout mice (Table 1.2).  Both 
knockouts of c-Jun and JunB are embryonic lethal at E12.5 and E10 respectively [136, 
137].  Knockout of c-Jun results in significant abnormalities in the heart and liver [136, 
138].  Defects in hepatocyte proliferation are maintained throughout adulthood, as 
perinatal liver specific deletion of c-Jun results in defects in liver regeneration following 
partial hepatectomy [139].  JunB knock-in can rescue the embryonic lethal phenotype of 
c-Jun knockout, however, mice still only survive a few days beyond birth [140].  
Interestingly, these mice show normal induction of Jun/Fos target genes, however, are 
unable to induce genes regulated by Jun/ATF dimers, suggesting only partial 
redundancy between these proteins.  Indeed, in other studies, c-Jun and JunB were 
shown to exert antagonistic effects [141, 142].  Overexpression of either c-Jun or JunB 
in transgenic mice shows no overt phenotype [143, 144].  Unlike c-Jun and JunB, JunD 
knockouts are viable; however, males exhibited impaired growth, hormone imbalances, 
and defects in reproduction due to faulty spermatogenesis [145]. 
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 FRA-1 is the only Fos protein whose knockout results in embryonic lethality.  This 
occurs at approximately E9.5 [146].  The embryonic lethality of FRA-1 knockout is due to 
defects in placental development [147, 148].  Interestingly, these defects can be 
completely rescued by providing wild-type extra-embryonic tissues during development.  
These rescued mice display no overt phenotype suggesting that beyond placental 
development FRA-1 expression may be dispensable for normal developmental 
processes [146].  Interestingly, expression of JunB in place of FRA-1 can also partially 
rescue development, suggesting that JunB and FRA-1 may have similar functions in 
early development [146].  The similar phenotypes between the knockouts of these mice 
further support this. Overexpression of FRA-1 results in accelerated osteoblast 
differentiation and increased bone formation in mice [149]. 
 Knockout of c-Fos results in viable mice, however, these mice lack osteoclasts 
[150, 151].  These mice also exhibit secondary alterations to the hematopoietic system, 
however; further studies have shown that c-Fos is dispensable for function of peripheral 
T-cells [152, 153].  Knock-in of FRA-1 in place of c-Fos is able to restore normal bone 
development demonstrating substantial redundancy between these proteins in normal 
development [154].  By comparison, overexpression of c-Fos further exacerbates the 
impact on bone development and promotes formation of osteosarcomas[155].   
 FosB null mice also develop normally, however, some studies have 
demonstrated that loss of FosB expression results in nurturing defects [156, 157]. 
Overexpression of FosB results in no discernable phenotype [144].  Unlike the other Fos 
proteins, FosB also exists as the variant ΔFosB.  Overexpression of this splice variant 
results in disruption of normal cellular differentiation particularly within osteoblasts and T-
cells [158, 159]. FRA-2 knockout results in disruptions to normal cartilaginous 
development and these mice die shortly after birth [160].  Overexpression of FRA-2 
results in ocular abnormalities [161]. 
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 These knockout studies demonstrate the diverse range of function associated 
with AP-1.  Despite the prediction that these proteins must functionally dimerize to exert 
functional effects, only JunB and FRA-1 knockouts exhibit similar phenotypes.  Knock-in 
studies have demonstrated that these proteins do retain functional equivalency under 
some circumstances, however, in many instances these knock-ins only rescue part of 
the knockout phenotype.  This suggests that these proteins also play unique roles within 
development.  For example, in fibroblasts c-Jun is a positive regulator of cellular 
proliferation, whereas both JunB and JunD are negative regulators [138, 162-165].  
These effects also appear to be context dependent as expression of c-Jun is critical for 
apoptosis in neuronal cells [166, 167].   
 
3.3 AP-1 in Tumorigenesis 
	
 The formation of cancer involves deregulation of numerous cellular pathways 
[168].  These include disruptions to normal cellular proliferation, evasion of the immune 
system, resistance to cell death, the induction of angiogenesis, and the activation of 
pathways involved in invasion and metastasis.  Interestingly, AP-1 has been shown to 
play a role in virtually every pathway associated with tumorigenesis [162, 164, 169-
172](Figure 1.11).   
 The oncogenic potential of both c-Jun and c-Fos is well known as the cellular 
homologs of the viral oncogenes v-Jun and v-Fos [125, 173]. The oncogenic potential of 
c-Fos is dependent on the ability of c-Fos to functionally dimerize, as well as the 
maintenance of several structural motifs within the N and C-terminus [174-177].  
Transformation of mammalian cells by c-Jun requires co-expression of oncogenic 
drivers, such as Ras, as well as the transactivation domain and the phospho-acceptor 
residues serine 63 and 73 [128, 178, 179]. Expression of c-Jun also results in decreased 
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expression of both p53 and p21 suggesting that c-Jun may interfere with normal tumor 
suppressor function [162]. Similar to c-Fos, FosB has also shown transformative 
potential in fibroblasts [180].  This potential also requires the presence of conserved 
motifs, particularly within the C-terminus [180-182]. 
 The transformative potential of the other fos proteins (FRA-1 and FRA-2) are 
both weak by comparison.  Overexpression of FRA-1 in fibroblasts does not result in 
significant morphological changes, but does promote anchorage-independent growth 
and tumor formation in nude mice [183, 184].  Despite the relatively weak transformation 
potential, expression of FRA-1 has also been shown to correlate with poor prognosis in 
breast cancer and drive an invasive phenotype [185-188].  Expression of FRA-1 in 
colorectal cancer also results in expression of genes involved in epithelial-to-
mesenchymal transition (EMT) [170, 189].  FRA-2 is capable of transformation in 
chicken fibroblasts, but not rat fibroblasts [190, 191].  Interestingly, both JunB and JunD 
lack any known transforming activity [143, 192].  Furthermore, several studies have 
indicated that these proteins may actually act as tumor suppressors [163, 165]. 
 
3.4 Dimer Specific Functions of AP-1 
	
 While studies of human tumors have shown that expression of Jun and Fos 
proteins is altered in a wide range of cancers, the role that AP-1 plays in many of these 
tumors remains poorly understood; particularly with regard to the specific dimers working 
within these cells [170, 186, 193-195].  Due to the diverse phenotypes associated with 
different Jun and Fos proteins, it is likely that the composition of AP-1 is a critical 
determinant of the function.  Based on the dimerization properties of Jun and Fos 
proteins, there are 18 potential dimer combinations; ignoring non-canonical dimers such 
as Jun:ATF and FRA1:Smad dimers (Figure 1.12).  Several studies have demonstrated 
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that dimer composition can influence the DNA binding properties of AP-1 [196-199].  
Studies using tether dimers of known composition have demonstrated that unique 
dimers regulate specific cellular effects, such as c-Jun:FRA-2 dimers inhibiting G0 arrest 
in 3T3 cells [198].  Jun and ATF dimers have been shown to specifically regulated 
growth factor independence [196].  FRA-1:Smad dimers have also shown to regulate 
invasive properties in response to TGFβ signaling [200]. As such, understanding the 
function of specific dimers and the hand-off from dimer to dimer remains of vital 
importance.  It is feasible that the induction of unique dimers in response to different 
stimuli is critical in mediating the appropriate response to the microenvironmental 
changes encountered by the cell.  Depending on the relative proportion of dimers, cells 
may proliferate, die, or migrate (Figure 1.13). 
  
	 40	
Table 1.2:  Phenotypes of AP-1 Genetically Modified Mice 
Table showing the associated phenotypes of published knockout and knock-in studies 




Phenotype of Knockout Mice 
Gene Phenotype Tissues Affected 
c-Jun Embryonic Lethal (E12.5)[136] Defects in heart and liver development 
JunB Embryonic Lethal (E10)[137] Placental Tissue 
JunD Male Sterility [145] Testis 
c-Fos Lack osteoclasts[150, 151] Bone 
FosB Nurturing defects[156] Brain 
FRA-1 Embryonic Lethal (E9.5)[146] Placental Tissue 
FRA-2 Death at Birth[160] Cartilage and Bone 
Phenotype of Knock-In Mice 
JunB for c-Jun 
Rescues embryonic lethality and 
some transcriptional targets.  
Mice die shortly after birth[140] 
Heart 
FRA-1 for c-Fos Rescues phenotype[154] None 
JunB for FRA-1 Partially rescues phenotype[146] None 
Phenotype of Overexpression Mice 
H2kb-cJun None[144] None 
UbC-JunB None[143] None 
H2kb-cFos Osteosarcoma[144] Bone 
H2kb-FRA1 Increased Bone formation[149] Bone 
H2kb-FosB None[144] None 
NSE-ΔFosB Defects in Osteoclast and T-cell Differentiation[158, 159] Bone and Thymus 




Figure 1.10:  Structure of the JUN and FOS protein Family 
 
Schematic diagrams representing conserved domains present within either the Jun or 
Fos family of proteins.  The percentage of similarity and identity is presented for each of 
these conserved regions.  Other critical regions are highlighted by name (Bzip domain, 
degrons, etc.).  Known sites of phosphorylation are highlighted by lollipops (green are 





























































Figure 1.11:  Role of AP-1 in Tumorigenesis 
The hallmarks of cancer are commonly used to highlight the deregulation of normal 
cellular processes in cancer.  Interestingly, AP-1 has been shown to impact nearly every 
proposed hallmark of cancer through the regulation of specific genes.  Other hallmarks 
have also been shown to induce AP-1 activity.  Known AP-1 target genes and their role 
in these hallmarks are presented in adapted figure from Hanahan and Weinberg[168].  
Effects in green indicate increased expression or activation of pathways whereas red 
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Figure 1.12:  Combinatorial Possibilities of AP-1 Dimers 
Based on the dimerization properties of Jun and Fos proteins there are 18 potential 
combinations for AP-1.  6 of these are “Jun:Jun” homodimers, whereas 12 are Jun:Fos 
heterodimers.  The total number of AP-1 dimer combinations can further expand based 






































18 Potential Dimer Combinations
(Excluding “Non-Canonical” AP-1 combinations)
Figure 1.12
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Figure 1.13:  Model of AP-1 Response to Differing Stimuli 
Hypothetical models of Jun and Fos protein expression in response to differing stimuli. 
Studies have shown that depending on the stimulus the induction of Jun and Fos 
proteins differs.  This suggests that the specific induction pattern of different Jun and Fos 
proteins may result in a different outcome in response to various stimuli.  These 
induction patterns may also regulate the hand-off from one dimer combination to 
another, as the relative contribution of each dimer to the total of AP-1 shifts to mediate a 



































































4.1 Structure and Function 
	
 The TP53 gene located on chromosome 17 encodes the tumor suppressor p53.  
This gene locus contains 11 exons, the first of which is non-coding [201].  The canonical 
p53 (also called FLp53, p53α, or TAp53α) consists of 393 amino acids and contains 6 
functional domains.  These include 2 N-terminal transactivation domains (TAD1 and 
TAD2), a proline rich domain, DNA binding domain, tetramerization domain, and a C-
terminal regulatory domain [201].  Depending on the use of internal start sites and 
alternative splice sites, the TP53 gene can encode at least 12 different variants of p53 
(Figure1.14) [202, 203].  These variants can dramatically alter function through changes 
in the normal domain structure of p53.  For example, Δ40p53 utilizes an internal start 
site within the full-length p53 sequence and this isoform lacks the first transactivation 
domain, as well as the Mdm2 binding site that normally regulates stability.  As a result, 
Δ40p53 exhibits different transcriptional activity and stability as compared to p53α [204-
207].   
 Under normal cellular conditions, p53 is a critical regulator of progression through 
the cell cycle and is activated in response to deviations from normal homeostasis [208].  
In the absence of stressors, p53 is maintained at very low levels, primarily through the 
regulatory effects of Mdm2 [209].  Mdm2 is an E3 ubiquitin ligase that regulates the 
turnover of p53 protein by promoting the ubiquitination and degradation of the protein 
[210].  This is accomplished through the binding of Mdm2 to p53 within TAD1.  Induction 
of cell stress, such as through DNA damage, results in activation of stress related 
kinases ATR and ATM and promotes phosphorylation of p53 [211, 212].  Downstream 
activation of Chk1 and Chk2 can further phosphorylate p53 [213].  These stress kinases 
also phosphorylate Mdm2 interfering with degradation of p53 [214] (Figure 1.15). Once 
p53 is stabilized it will oligomerize to form tetramers and bind to the promoters of specific 
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targets, such as p21 or Puma, to promote either growth arrest and DNA repair or induce 
apoptosis [208].  Increased p53 activity also results in upregulation of Mdm2 to form a 
regulatory feedback loop to control p53 expression.  As a result, the p53 response 
exhibits pulsatile dynamics with cyclical peaks and valleys of p53 expression allowing for 
multiple checks for lesions before re-entry into the cell cycle [215]. 
 
4.2 Loss of p53 function in Cancer 
	
Loss of p53 function plays a major role in the development of most cancers and 
can occur through a number of mechanisms.  Destabilization of the p53 protein, such as 
through E6 and E7 viral oncoproteins has been shown to play a major role in the 
development of cervical cancer following infection with the human papilloma virus (HPV) 
[216, 217].  Expression of these proteins is also commonly used in the process of 
immortalizing normal human cells for in vitro study [218, 219].  Expression of other viral 
proteins can also inactivate p53 including SV40 large T-antigen and adenovirus E1B 
protein [220].  Likewise, overexpression of Mdm2 has been observed in several cancers 
as a mechanism of decreasing p53 expression [221, 222].  Homologs of Mdm2, like 
MdmX, can also act as negative regulators of p53 and are also upregulated in 
neoplasms [223].  Methylation of the p53 promoter element can also drive loss of p53 
expression [224-226].  Finally, loss of p53 function can occur through deletion, nonsense 
mutations, and missense mutations [227].  The vast majority of these mutations occur 
within the DNA binding domain of p53 and have long been thought to result in loss of 
DNA binding capacity (Figure 1.16).  In particular there are approximately 6 hotspots that 
are consistently mutated including R175, G245, R248, R249, R273, and R282, all of 
which are present in the DNA binding domain. 
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Initially, it was postulated that tumor development required “two-hits” of tumor 
suppressors for complete loss of function and tumor progression [228, 229].  While this 
model holds true in some cases, as research has progressed exceptions to this rule 
have been found.  These genes exhibit a haploinsufficient phenotype, suggesting that 
one functional allele fails to generate enough product to reach a normal threshold. 
Several studies have demonstrated that p53 exhibits a haploinsufficient phenotype [230, 
231].  As a result, p53 germline mutations result in significantly increased risks for the 
development of cancer, both through haploinsufficiency and the increased likelihood of a 
secondary hit of the remaining functional allele [232].  
 
4.3 p53 as a gain-of-function oncogene 
	
Missense mutations of p53 were long considered loss-of-function mutations that 
promoted tumor progression by removing normal cellular checkpoints regulated by p53 
through abrogation of p53’s DNA binding capacity.  However, unlike most tumor 
suppressors, p53 mutations are primarily single amino acid substitutions as opposed to 
nonsense mutations that yield either a truncated protein or no product at all.  
Explorations into the activity of p53 mutants have suggested that mutant p53 may 
function as an oncogene in a gain-of-function manner (Figure 1.17) [233-238].   
Early studies in mice found that the presence of a mutant p53 allele was not 
equivalent to a p53 null allele [239].  Similarly, in the KPC mouse model of pancreatic 
cancer, expression of mutant p53 results in a widely metastatic disease whereas p53 
knockout mice exhibit a more localized disease [15].  This phenotype is also observed in 
other mouse models of cancer [240, 241] While missense mutations alter the structure 
and residues involved in DNA binding, several studies have demonstrated that mutant 
p53 retains some DNA binding to strong p53 promoters like the p21 promoter[242].  
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Interestingly, these mutants often lose the capacity to bind the promoter of the pro-
apoptotic protein Bax, suggesting that mutant p53 preferentially promotes survival 
signaling while impairing apoptosis.  These mutations also result in gain-of-function 
binding to new DNA elements in a structure dependent manner[237, 243]. 
 Beyond alterations to the DNA binding properties, mutant p53 also exhibits 
enhanced stability and increased expression is often observed within tumors.  This 
appears to be due in part to impaired regulatory feedback between Mdm2 and p53 [244].  
Mutation of p53 also results in novel interactions with new partners to drive pro-
tumorigenic effects [245-247].  A subset of p53 mutants gain the ability to associate with 
related family members p63 and p73 to inhibit growth suppression [248].  A number of 
other mutants have also shown the capacity to interact with the transcription factor SP-1 
to drive expression of SP-1 genes [249, 250]. Other studies have implicated mutant p53 
in alterations to DNA synthesis and proliferation, chemoresistance, acquisition of stem 
cell characteristics, and induction of angiogenesis [251-254].  As a result, reactivating 
wildtype p53 function through the refolding of mutant p53 is a widely explored 
therapeutic option [255-258]. 
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Figure 1.14:  Structure of Full-Length p53 and its Variants 
A schematic diagram presenting the domain structure of full-length p53 and its variants 
from internal start sites or alternative splicing.  Δ variants arise through the use of 
internal ATG start sites within the amino acid sequence, whereas β and γ variants arise 
from alternative splicing of C-terminal exons.  As a result, the TP53 gene can give rise to 


































Figure 1.15:  p53 Response to DNA Damage 
In response to DNA damage, ATM is activated and phosphorylates Chk1.  Both Chk1 
and ATM can phosphorylate p53 resulting in stabilization of the protein.  ATM also 
phosphorylates Mdm2 to inhibit its activity and further stabilize p53.  P53 then can 
induce transcription of either survival/growth arrest genes like p21 or induce cell death 
pathways through induction of pro-apoptotic proteins.  Increased p53 activity also drives 
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Figure 1.16:  Mapping of p53 Mutations 
Schematic representation of known mutations in p53 in pancreatic ductal 
adenocarcinoma.  Length of each lollipop indicates the relative proportion of mutation.  
Hotspot mutations typically occur within the DNA binding domain of p53, whereas 
mutations in other domains are uncommon.  Data were collected from cBioportal and 
from the TCGA. 
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Figure 1.17:  Mechanisms of Mutant p53 Gain-of-Function Effects 
Mutant p53 has been proposed to gain oncogenic potential through a number of different 
mechanisms.  A) Binding to p63 and p73 and inhibiting transcription of downstream 
targets.  B) Association with novel transcription factor partners to alter expression of 
their targets.  C) Binding of novel DNA elements in a structure specific fashion.  D) 
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Based on the known role of MUC1 as an integrator of cellular signals and known 
associations with both AP-1 and p53, we sought to explore how MUC1 alters the 
formation and regulation of these transcriptional complexes.  We focused upon how the 
MUC1 cytoplasmic tail is capable of integrating multiple signals to initiate appropriate 
downstream signaling.  Furthermore, we investigated how expression of MUC1 impacts 
AP-1 with special focus on roles in migration, invasion, and metastasis in pancreatic 
cancer.  Lastly, we examined how the mutational status of p53 can influences its 
association with the cytoplasmic tail of MUC1 and the potential influence of gain-of-








The anti-MUC1 antibody CT2 was generously provided by Dr. Sandra J Gendler or 
ordered from Abcam (ab80952).  Phospho-specific antibodies against the MUC1 
cytoplasmic tail were previously generated within the lab.  Antibodies against c-Jun and 
phosphoSerine73 c-Jun were obtained from Abcam (ab31419, ab32447).  Antibodies 
against phosphoFRA-1, phospho-c-Fos, ERK, and phosphoERK were purchased from 
Cell Signaling (#5841, #5348, #9107, and #4377 respectively). Antibodies measuring the 
DNA damage response (pChk1, pChk2, phospho-p53, PUMA, and p21) were also 
obtained from Cell Signaling (#9947S, #12450S, and #2947S respectively).  Antibodies 
against Cyclin D1 and Cyclin A were purchased from Cell Signaling (#2926 and #4656 
respectively).  FRA-1, c-Fos, and H2B were obtained from Santa Cruz (sc-28310, sc-
8047, sc-8650) and ATF2 from Novus Biologicals (H00001386-M02).  β-actin, p53 (DO-
1), and Flag (M2) antibodies were obtained from Sigma Aldrich.  
 
BET Inhibitor Treatments 
 BET inhibitors JQ-1 and OTX015 were purchased from SelleckChem (Cat.No 
S7110 and S7360).  Inhibitors were suspended in DMSO and stored as aliquots until 
use.  Cells received either inhibitor treatment or DMSO control at the indicated doses.  
Cells were only treated once per experiment. 
 
Cell Culture 
Panc1, Colo357, and AsPC-1 cells were obtained from American Type Culture 
Collection and S2013 cells were obtained from the originator of the line [69].   
S2013.Neo and MIF were generated as previously described [102]. Panc1.MUC1 and 
Neo were generated from stable transfection of pSIN-ires-neo using lentiviral 
transduction.  Panc1.MUC1-FRA1, Panc1.Neo-FRA1, S2013.Neo-FRA1, and 
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S2013.MIF-FRA1 lines were generated by stable transfection of pLVX.puro using 
lentiviral transduction. FRA-1 knockdown was performed using the previously 
characterized shRNA TRCN0000019539 [259] or scrambled control purchased from 
OpenBiosystems.    Cells were selected in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 4 µg/ml Puromycin, 10% fetal bovine serum (FBS), and 1X 
HyClone penicillin/streptomycin mix (100 U/ml penicillin and 100 µg/ml).  
Colo357, Panc1, and HPDE inducible p53 cell lines were generated by 
sequential lentiviral transduction of pLVX.Tet-ON, and pLVX.Tight-puro generously 
provided by Dr. Angie Rizzino, followed by sequential selection in DMEM supplemented 
with 1000 µg/ml G418 or 4 µg/ml Puromycin. Once selection had occurred cells were 
maintained in 10% DMEM supplemented with HyClone pen/strep mix.  Cells were 
maintained at 37°C in a humidified environment with 5% CO2. 
 
Cell Cycle Analysis 
 Cell cycle analysis was performed using the propidium iodide flow cytometry kit 
purchased from Abcam (ab139418).  Briefly, supernatant was removed and adherent 
cells were trypsinized and removed from plate by rinsing with original supernatant.  Total 
cells were counted and 1 million cells were pelleted and fixed with 70% EtOH.  After all 
time points were collected, cells were prepared for flow cytometry.  Fixed cells were 
pelleted and washed 2X in 1X PBS.  Cells were then resuspended in 400 µl 1X 
Propidium Iodide + RNase Staining Solution.  Cells were incubated in the dark for 30 
minutes at 37 °C before being taking to the UNMC flow cytometry core for analysis.  
Average percentages of cells in each phase were then plotted for each treatment group. 
 
Chromatin Shearing and Chromatin Immunoprecipitation (ChIP) 
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 A 15 cm dish of cells was fixed in 1% formaldehyde at room temperature for 10 
minutes according to the MagnaChIP protocol (Millipore).  After fixation cells were 
quenched with 1X glycine from kit.  Cells were washed and collected in 1X PBS 
containing protease inhibitors.  Cells were than pelleted and supernatant removed.  500 
µl of cell lysis buffer was added for each 15 cm dish.  Cells were incubated on ice for 15 
minutes before being pelleted again.  500 µl of nuclear lysis buffer was added and lysate 
was aliquoted into Covaris AFA sonication tubes.  DNA shearing was done for 6 minutes 
on the Covaris S2 sonicator with 2% duty cycle, 3 intensity, and 200 cycles per burst.  
Shearing was assessed using agarose gel and chromatin stored at -80°C until use.  
Chromatin immunoprecipitation was performed according to MagnaChIP (Millipore) 
protocol using 5 µg FRA-1 (sc-605) antibody or IgG control per 50 µl chromatin.  Eluted 
DNA was analyzed by qRT-PCR and compared to both input and IgG controls. 
 
Co-immunoprecipitation 
Cells were grown to 80-90% confluence and lysed in co-immunoprecipitation 
buffer (50 mM Tris-Cl, 150 mM NaCl, 0.5% NP40, pH 8.0) in the presence of protease 
and phosphatase inhibitors (ThermoFisher 78440).  Buffer was adjusted to 300 mM 
NaCl to promote extraction of nuclear proteins.  Lysates were incubated on ice for 30 
minutes and insoluble debris removed by centrifugation at 16,000g.  300 µl of lysate was 
incubated with Protein G beads (ThermoFisher 1003D) and antibodies against the 
protein of interest or an IgG control  at 4°C for 2 hours to form complexes.  For p53-Flag 
pulldown, M2 agarose beads were used instead of Protein G.  Beads were washed 3X 
with Co-IP wash buffer (50 mM Tris-Cl, 150 mM NaCl, 0.1% NP40) and proteins eluted 
by boiling in SDS sample buffer.  Each co-immunoprecipitation study was performed 




FRA-1 constructs were designed by PCR amplification of FRA-1 cDNA 
purchased from OpenBiosystems.  Primers used were designed for placement of a HA-
epitope tag on the C-terminus of FRA-1.  Amplified fragments were then restriction 
digested and ligated into pLVX.puro vector for lentiviral transduction.  DNA sequencing 
of the plasmid confirmed appropriate sequence.  
Inducible p53 constructs were designed by PCR amplification of cDNA from 
OpenBiosystems and a C-terminal 3X-Flag tag added through PCR.  Amplified products 
were cloned into the pLVX.Tight-puro construct from Clontech.  Specific p53 mutants 
were generated using the site-directed mutagenesis kit from Agilent and all mutants 
were confirmed by DNA sequencing.   
Homologous arm constructs for CRISPR mediated fusion protein knock-ins were 
designed using primers specific for regions upstream and downstream of the predicted 
CRISPR cut site.  Amplicons were approximately 1.5 kb.  PCR amplification of these 
regions was performed following isolation of genomic DNA from cell lines.  Amplicons 
were then cloned into original AAV vector provided by Dr. John Albeck. 
 
DNA Damage Studies 
 Cells were exposed to either UV or X-ray irradiation.  X-ray irradiation was 
performed using RS-2000 irradiator in the Biological Irradiation Core and cells were 
treated with the indicated doses.  UV damage was induced by exposure to DNA gel box 
for 5 minutes.  Following DNA damage cells were returned to the incubator for 1 hour 
before lysis and examination of DNA damage response by western blot analysis. 
 
Doxycycline Treatment of Inducible Cell Lines 
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 Fresh doxycycline was prepared in autoclaved water and stored as aliquots until 
use.  Cells were primarily treated with 1 µg/ml doxycycline unless otherwise indicated.  
Cells were treated for 24 hours prior to analysis of p53 expression and downstream 
effects except for long-term studies.  For studies longer than 24 hours, media was 
replaced with fresh doxycycline containing media every 24 hours to retain expression of 
p53 as doxycycline degraded. 
 
Immunoblotting 
Proteins were transferred from gels to Immobilon-FL PVDF membrane using the 
Bio-Rad transfer system at 100V, 0.3 A, for 70 minutes. Membranes were rinsed in 1X 
PBS then blocked for 1 hour in a 1:1 mixture of 1X PBS and Licor Blocking buffer.  
Primary antibodies were incubated for 1 hour in 0.1% PBST:Licor buffer.  All primary 
antibodies were used at a concentration of 1 µg/ml.  Membranes were washed three 
times with 0.1% PBST.  Secondary antibodies were conjugated to IrDyes (Licor) and 
incubated for 1 hour in the dark in 0.1% PBST/Licor buffer with 0.01% SDS to reduce 
background.  Blots were washed three more times, rinsed with 1X PBS, and visualized 
using the Odyssey Imaging System. 
 
Immunohistochemistry 
Slides containing primary pancreatic tumor, liver metastases, or uninvolved 
pancreas were obtained from the UNMC Rapid Autopsy Program.  Staining was 
performed using the Dako Envision+ kit (K4006) with a hematoxylin counter-stain.  Anti-
FRA-1 (sc-28310), Anti-ZEB1 (ab180905), Anti-slug (ab27568) and IgG control were 




Invasion and migration assays 
Assays were carried out using matrigel invasion plates or control migration plates 
from BD Biosciences (#354480 and #354578 respectively).  Cells were grown to 
approximately 60% confluence and serum starved 24 hours prior to assay.  Treated cells 
received a 2-hour pretreatment of 10µM U0126 (Sigma).  Prior to plating, matrigel matrix 
in invasion plates was rehydrated for 2-4 hours with serum free media at 37°C, migration 
plates required no pre-treatment. 100,000 cells per well were plated for invasion assays 
and 25,000 cells per well for migration assays.  Chemoattractant in the lower well was 
10% FBS containing DMEM.  Cells were incubated at 37°C for 24 hours, then inserts 
were washed and stained using the DiffQuick staining kit.  Membranes were dried and 
mounted on slides for quantification.  Each experimental group was examined in two 
independent experiments with each group plated in triplicate.  Stastical analysis was 
performed using 2-tailed student’s t-test. 
 
KPC MUC1 knockout mice and cell lines 
KPC mice were bred at UNMC to carry the PDX-1-Cre transgene [260], the LSL-
KRASG12D knock-in mutation [261] and the LSL-Trp53R172H knock-in mutation [262]. In 
the context of the KPC background, mice were bred to the Muc1 knockout mouse [263] 
to generate KPC mice that express Mucin-1 (KPC WT) or are deficient in Mucin-1 
expression (KPC KO).  Cell lines were derived from primary tumors of each genotype 
and utilized for further analysis.  Cell lines were collected by collagenase digestion of 





 Lentivirus was generated through transfection of 293A cells with 3:1:4 ratio of 
packing vectors psPAX2 and pMD2.G along with the appropriate lentiviral vector 
containing our sequence of interest.  Transfection was performed using the X-fect 
protocol from Clontech.  Lentivirus was collected at 24, 48, and 72 hours post-
transfection.  Virus containing media was passed through a 0.45 µm SFCA filter and 
polybrene (6 µg/ml) added to the filtered media.  Viral media was then applied to 
transduced cells. 
 
Methylene Blue Proliferation Assay[264] 
2,000 cells were plated in 6 wells of a 96-well plate for each cell line.  One plate 
was used for each time point measured (0, 24, 48, 72, and 96 hours [also 120 and 144 
hours in Colo357 studies]).  After each time point cells were fixed with formalin and kept 
at 4° until all time points were taken.  To generate the 0 hour time point the cells were 
allowed to adhere for two hours and then immediately fixed.  Following fixation cells 
were stained for 30 minutes with 1% methylene blue in 0.01M borate buffer (pH8.5).  
Plates were rinsed 4 times in 0.01M borate buffer and the dye eluted with 100 µl of 1:1 
ethanol and 0.1M HCl.  The absorbance at 650 nm was measured with a plate reader 
and results normalized to background.  2-way ANOVA was used to assess differences in 
proliferation between multiple cell types and treatment groups. 
 
Orthotopic Mouse Studies 
All mouse studies were performed according to UNMC IACUC specifications.  
150,000 tumor cells were injected orthotopically into the pancreas of nude mice. 
S2013.Neo and MIF cell lines and their FRA-1 knockdown counterparts were utilized for 
the study.  Groups consisted of 12-13 mice for a total of 50 mice overall, all mice were 
female.  Tumors were allowed to develop for 30 days, at which time mice were sacrificed 
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and tumors measured.  Presence of ascites and metastasis was initially assessed based 
on gross observation during necropsy.  Tissues for each metastatic site and primary 
tumor were formalin fixed.  The UNMC tissue sciences core facility cut and stained H&E 
slides for each sample in the experiment.  Metastases were confirmed by microscopy 
before final scoring.  Statistical analysis of differences in tumor growth was assessed 
using ANOVA and Bonferroni method for multiple comparisons. 
 
Phosphatase Assay: 
 MUC1 wild type mouse stomach was lysed into T-Cell Protein Tyrosine 
Phosphatase buffer  (50 mM Tris-HCl, 100 mM NaCl, 2 mM Na2EDTA, 5 mM DTT, 
0.01% Brij35, pH 7.5) supplemented with protease inhibitor cocktail tablet (Roche) using 
a 27 gauge needle for full lysis.  Lysates were divided evenly into 2 microcentrifuge 
tubes with 1 receiving 20 µl (200 U) T-Cell Protein Tyrosine Phosphatase (New England 
Biolabs) and the other receiving a phosphatase inhibitor to reduce active phosphatase 
activity in the whole lysate.  Samples were incubated at 30°C in a water bath for 3 hours 
to yield maximal dephosphorylation.  Samples were then buffer exchanged into 2D-
Xtract buffer using Zeba desalting columns and analyzed with 2D gel electrophoresis. 
 
Proximity Ligation Assay (PLA) 
All PLA reagents used were from Duolink PLA kit.  Cells were grown in 12-well 
plates on poly-lysine coated slides.  Cells were fixed with 4% PFA supplemented with 
120 mM sucrose.  The reaction was quenched by removal of PFA and addition of 0.1 M 
glycine for 5 minutes followed washes with 1X PBS.  Cells were permeabilized using 500 
µl of 0.15% Triton-X-100 with 1% BSA in 1X PBS for 15 minutes then blocked with 1 
drop of blocking solution for 30 minutes at 37°C.  Blocking solution was removed and 
coverslips incubated with the primary antibodies in antibody diluent (1:200) overnight at 
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4°C. After incubation, coverslips were washed three times with PLA wash buffer A for 5 
minutes.   PLA secondary probes were added and incubated at 37°C for 1 hour in the 
dark.  Coverslips were washed twice more with PLA wash buffer A and ligation reaction 
mix was added to the coverslips for 30 minutes at 37°C.  After two more washes in 
buffer A the amplification-polymerase solution was added for 100 minutes at 37°C. 
Coverslips were washed twice in 1X PLA wash buffer B then once in 0.1X buffer B. 
Coverslips were mounted with Fluoromount G with DAPI.  Results were visualized with 
confocal microscopy and the interactions were quantified using Blobfinder.  All 
experimental groups were performed in quadruplicate and multiple independent fields 
per slide were used for quantification.  Statistical analysis was performed by 2-tailed 
student’s t-test. 
 
Purification of Recombinant MUC1 
 Recombinant expression of MUC1 was induced in C41 or C43 E.coli through 
transformation with the pGEX4T-1 plasmid.  The full-length cDNA sequence of the 
MUC1 C-terminus was optimized for E.coli expression before being cloned into this 
vector to generate a C-terminally tagged GST-MUC1 construct.   GST-purification kit 
was ordered from Clontech (Cat# 635619) and purification of recombinant protein was 
performed according to the provided protocol.  Pulldown of recombinant MUC1 was 
confirmed by western blot analysis of elution fractions. 
 
R programming 
 All applications involving R programming language were performed using 
RStudio.  Heatmaps were generated in R for all Immunohistochemistry experiments.  
Hierarchical clustering was also performed using R programming language to generate 
the distance scores and cluster the individual tumors utilized in Bailey, et al[18].  
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Individual box plots for each gene were also designed using R programming to cluster 
each tumor into it’s identified subtype and plot the normalized RNA-seq expression 
values. 
 
RNA Isolation, RT-PCR, and RNA-seq 
Cells were grown to 80-90% confluence on 15 cm dishes, rinsed with 1X PBS 
and RNA isolated using the Qiagen RNeasy kit.  For inducible p53 studies, cells were 
treated with indicated doses of doxycycline for 24 hours prior to RNA isolation.  Isolated 
RNA was aliquoted and stored at -80 until use.  RNA was converted to cDNA using the 
Verso cDNA kit (ThermoFisher) and cDNA was stored at -20 until use.  All RT-PCR 
primers were obtained from PrimerBank. RT-PCR for each primer set was performed in 
triplicate and Sybr Green was used for signal detection.  Fold change was calculated 
using the ΔΔCt method and converted to log2fold change or normalized to 18s rRNA for 
plotting multiple genes on the same graph.  For single comparisons statistical 
significance was assessed by student’s t-test.  For multiple comparisons 2-way ANOVA 
was used.  For RNA-seq assays, RNA was collected from 3 biological replicates using 
the Qiagen RNeasy kit and submitted to the UNMC sequencing core for library 
preparation and sequencing using the Illumina HiSeq2500.  Results were analyzed using 
tophat/cutdiff and edgeR analysis programs by the UNMC bioinformatics core.  
Differentially expressed genes were then run through Qiagen’s Ingenuity Pathway 
Analysis to identify cellular pathways that were altered between cell lines[265]. 
 
Subcellular Fractionation 
Cytoplasmic and Nuclear fractions were obtained using the nuclear fractionation 
protocol from Abcam.  Cells were grown to 80-90% confluence and lysed into Buffer A 
(10mM HEPES, 1.5 mM MgCl2, 10mM KCl, 0.5mM DTT, and 0.5% NP40) and then 
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incubated on ice for 30 minutes.  Lysates were spun down at 3000 rpm for 10 minutes at 
4°C to pellet nuclei.  The supernatant was removed as the cytoplasmic fraction and the 
nuclear pellet was washed 3 times in Buffer A to remove potential contaminants.  The 
nuclear pellet was lysed in Buffer B (5mM HEPES, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM 
DTT, 26% glycerol, supplemented with 300mM NaCl added fresh).  To ensure lysis, the 
nuclear pellet was passed through a 25-gauge needle and the lysates incubated on ice 
for 15 minutes.  Lysates were then spun down at 16,000g for 15 minutes to pellet 
insoluble debris.  The supernatant was collected as the nuclear fraction.  Fraction purity 
was assessed by western blotting with an antibody to Histone 2B. 
 
2D gel electrophoresis 
Cells were grown in 150 mm dishes until approximately 90% confluent.  Cells 
were washed with 1X PBS and lysed with 8M urea/thiourea containing 2D-Xtract buffer 
(G-Biosciences) supplemented with complete protease and phosphatase inhibitor 
(ThermoScientific) and removed from the dish by scraping.  Mouse tissues were 
homogenized using dounce homogenizers directly into 2D-Xtract buffer supplemented 
with protease and phosphatase inhibitors.  The resulting lysates, cells and tissue, were 
then alkylated with 5 µl/ml N, N-dimethylacrylamide and placed on a rotator for 20 
minutes at room temperature.  Alkylated samples were quenched with DTT to a final 
concentration of 200 mM, and centrifuged at 13,000 rpm for 30 minutes to pellet 
remaining debris.  Protein concentration was determined by Bradford analysis and 
diluted to a loading concentration of 175 µg/ 155 µl, with 1 µl of the appropriate pH 
ampholytes (Invitrogen 3-10 or 4-7) and 1 µl 0.25% Bromophenol blue.  155 µl of sample 
was loaded into each lane with the IPG Zoom strip and allowed to rehydrate the gel strip 
for a minimum of 2 hours.  Following rehydration, loading wells were removed and filter 
paper saturated with 600 µl DI water was affixed to the designated location.  Zoom tray 
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was loaded into the running apparatus and the outer well filled with 600 ml DI water.  
Isoelectric focusing was performed per manufacturers specifications (Zoom IPG runner, 
Invitrogen). Following first dimension electrophoresis, IPG strips were equilibrated in 10 
ml 1X SDS sample buffer with 100 mM DTT for 12 minutes then with a 12 minute 
equilibration in 10 ml 1X SDS sample buffer with 232 µg iodoacetamide. IPG strips were 
loaded into 4-12% Bis-Tris Zoom Gels, IPG well (Invitrogen) and sealed with 0.5% MES 
or MOPS agarose, depending on second dimension running buffer.  Gels were loaded 
onto the Invitrogen running apparatus with MES or MOPS running buffer depending on 
















Chapter III:  Post-translational Modification of the MUC1 




1.  Key Findings	
• MUC1 exists in an extensively phosphorylated state in normal mouse pancreas 
• Alterations to the surrounding environment or transformation alters the post-
translational modification of MUC1 
• MUC1.CT is N-glycosylated and this form appears to translocate to the nucleus 
• Processing of MUC1 does not appear to involve TACE, however, another self-
cleaving module may be present within the MUC1.CT 
• MUC1 splice variants exhibit extensive phosphorylation suggesting a functional 






 The cytoplasmic tail of MUC1 is postulated to act as a sensor of the extracellular 
environment; integrating information from the surroundings and propagating intracellular 
signaling events to drive cellular responses [26].  While numerous studies have 
demonstrated specific phosphorylation events within the cytoplasmic tail and the 
corresponding impact on cell signaling, no studies have evaluated the global 
phosphorylation status of MUC1 [77-79, 82, 100, 104, 266].  The cytoplasmic tail of 
MUC1 contains 21 potentially phosphorylated residues.  This allows for a potential of 
more than 2 million combinatorial patterns of phosphorylation.  This patterning may 
explain the capacity of MUC1 to alter many distinct pathways, in many instances 
involving phosphorylation of the same residue [20, 26, 77, 100]. 
 Phosphorylation of MUC1 is thought to be critical for it to translocate to the 
nucleus where it functions as a transcriptional co-regulator in association with 
transcription factors, such as p53 and β-catenin [26].  Interestingly, the precise fragment 
of MUC1 that translocates within the nucleus remains unknown.  It has been proposed 
that MUC1 may potentially undergo a proteolytic cleavage event, similar to Notch 
signaling, and only the cytoplasmic tail may go to the nucleus [267].  Another possibility 
is the endosomal transport of MUC1 into the nucleus, similar to the mechanism of ErbB2 
translocation [90].   
 Further adding to the complexity of signaling through MUC1 is the presence of 
several splice variants [268].  In many instances, these splice variants retain at least a 
portion of the cytoplasmic tail, potentially allowing for distinct signaling mechanisms.  
The C-terminal subunit of MUC1 also contains a consensus sequence for N-linked 
glycosylation.  These glycosylation sites may be critical mediators of interactions with 
various signaling partners in the extracellular compartment. 
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Given the role of MUC1 in oncogenic signaling, we sought to explore the range of 
post-translational modifications on MUC1.  Presumably, modification of these sites 
allows for MUC1 to relay a wide array of signals into the cell.  To assess these 
modifications, we utilized 2D gel electrophoresis, as well as phosphorylation specific 
antibodies in an attempt to map the patterns observed on MUC1.  We performed 
additional studies evaluating the potential for N-glycosylation of the MUC1.CT, as well as 
the possibility of proteolytic cleavage of the cytoplasmic tail.  We found that MUC1 exists 
in an extensively phosphorylated state, and that this phosphorylation can be impacted by 
cellular transformation or stimulation with different factors.  Furthermore, MUC1 appears 
to translocate to the nucleus as 3 distinct forms, one of which is N-glycosylated.  These 
forms are apparently independent of proteolytic cleavage by ADAM17; however, in vitro 
studies suggest that self-cleavage effects may occur within the cytoplasmic tail as a 
result of chemical reactions involving the cysteine residues of the cytoplasmic tail.  
Furthermore, MUC1 splice variants are also extensively phosphorylated suggesting 




MUC1.CT is Extensively Phosphorylated in Response to Environmental Factors 
The C-terminal subunit of MUC1 (MUC1.CT) contains a wide array of potential 
post-translational modification sites.  In particular, the cytoplasmic tail contains several 
serine, threonine, and tyrosine residues (Figure 3.1A).  To assess the post-translational 
status of MUC1, we performed 2D gel electrophoresis to identify changes in predicted 
size or isoelectric point in normal mouse pancreas and in KPC tumors.  We observed the 
presence of 3 distinct bands of approximately 25, 20 and 15 kDa deviating from the 
predicted molecular weight of 17 kDa of the 158 amino acid, MUC1.CT.  This was true 
	 80	
for both normal mouse pancreas and KPC pancreatic tumors.  We also observed 
significant deviations from the predicted isoelectric point of 6.4.  Phosphorylation is 
predicted to cause a decrease in the observed isoelectric point [269].  To test whether 
these deviations were the result of phosphorylation, we treated mouse pancreas extracts 
with 200 U T-cell tyrosine phosphatase for 3 hours at 30°C and repeated the 2D gel 
analysis.  Treatment resulted in a shift of isoforms from an apparent PI of 4.0-4.6 back 
towards a range of 4.9-6.0, approaching the predicted isoelectric point of 6.4, though this 
shift was incomplete, suggesting the presence of additional modifications of serine and 
threonine residues on the MUC1.CT (Figure 3.1B).  Interestingly, KPC tumors exhibited 
higher levels of the lower isoelectric point forms than normal mouse pancreas, 
suggesting hyperphosphorylation in these tumors. 
To further assess potential phosphorylation events of MUC1.CT, we performed 
western blots of normal mouse pancreas utilizing phosphospecific antibodies raised 
against unique MUC1 phosphoepitopes.  We observed positive results with antibodies 
against a number of sites, suggesting that MUC1.CT is indeed extensively 
phosphorylated at a variety of sites (Figure 3.1C).  In addition, the different gel mobilities 
shown in 3.1.C suggest that the rather broad bands observed with antibodies against the 
MUC1CT (e.g. Figure 3.1.B) are comprised of isoforms of MUC1CT that are differentially 
phosphorylated at multiple sites in different combinations.   To confirm that receptor 
tyrosine kinases and other stimuli signal through MUC1CT, we evaluated the effect of 
stimulating MUC1 expressing cells with EGF.  Stimulation of cells with either FBS or 
EGF resulted in differential patterning of MUC1 phosphorylation events, suggesting that 
different stimuli promote different phosphorylation patterns of MUC1.CT (Figure 3.2). 
 
MUC1.CT is N-glycosylated and Present in the Nucleus 
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 The juxtamembrane portion of the extracellular domain of the MUC1.CT contains 
a consensus site for N-glycosylation (NXS/T).  Previous studies have suggested that 
MUC1.CT is N-glycosylated at this site [270].  We sought to confirm the presence of N-
linked glycosylation at this site.  Furthermore, we wanted to identify whether this form 
was present within the nucleus, given the previously reported finding that the 
extracellular part of β-dystroglycan can traffic to the nucleus [271].  We performed 
western blot analysis of normal mouse pancreas extract following treatment with the 
glycosidase PNGase F (Figure 3.3A).  PNGase F treatment resulted in a decrease in the 
apparent molecular weight of the 25 kDa band to the 20 kDa band, indicating that 
MUC1.CT is N-glycosylated.  To test whether this form is present within the nucleus, we 
performed subcellular fractionation of S2013.Neo and MIF cells (Figure 3.3B) and 
treated the nuclear fraction of S2013.MIF cells with PNGase F, followed by western blot 
analysis.  PNGase treatment induced a shift of MUC1.CT from 25 to 20 kDa indicating 
loss of N-glycosylation and suggesting that this form is present within the nucleus 
(Figure 3.3C).  This supports the hypothesis that the 25 kDa band of MUC1 seen in 
these experiments contains the C-terminus with N-glycosylation, whereas the 20 kDa 
band contains non-glycosylated forms of MUC1.CT.   
 
MUC1.CT Processing is Unaffected by a TACE Inhibitor 
 There have been reports of putative cleavage sites within the C-terminal portion 
of MUC1 for the ADAM17 protease, also called TACE [272].  This cleavage results in 
truncation of the predicted 58 amino acid extracellular domain of MUC1CT.  As we had 
previously identified the 25 and 20 kDa bands of MUC1.CT, we sought to examine 
whether cleavage by TACE was responsible for the formation of smaller bands, including 
the 15 kDa band.  We treated S2013.MIF cells with the TACE inhibitor, TAPI-2, at 
increasing doses for 12 or 24 hours and monitored the processing of MUC1 by western 
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blot analysis (Figure 3.4).  We observed no significant differences in any of the MUC1 
bands detected by CT2.  This suggests that processing by TACE is not responsible for 
the 15 kDa form of MUC1.CT. 
 The cysteine residues of MUC1.CT have been suggested to critically regulate a 
number of processes, including dimerization.  Interestingly, several studies have shown 
nucleophilic chemical reactions within proteins resulting in self-cleavage events (Figure 
3.5A).  These excised segments are termed inteins and the cleavage events caused by 
this chemical reaction can be catalyzed by the addition of reducing agents [273].  To 
examine the potential dimerization of MUC1 in vitro we have purified recombinant MUC1 
from E.coli cells and examined the properties under reducing or non-reducing conditions.  
Under non-reducing conditions, we observe an approximately 40 kDa band consistent 
with a dimer of MUC1.  Interestingly, we have observed in initial studies with 
recombinant MUC1.CT that the presence of DTT results in formation of a cleavage 
fragment of approximately 15 kDa and this is absent in non-reduced conditions, 
suggesting the possibility of a self-cleavage event involving the cysteine residues of 
MUC1 (Figure 3.5B).  Future studies using cysteine mutants may help to confirm this 
possibility, though serine residues have also been shown to be involved in this type of 
cleavage. 
 
MUC1 Splice Variants are Extensively Phosphorylated 
 The MUC1 gene contains 7 exons and can be alternatively spliced into a wide 
variety of alternative products [268].  Many of these variants retain the cytoplasmic tail 
suggesting the possibility for differential signaling depending on the splice variant.  While 
the signaling capacity of MUC1 has been well studied, the potential for signaling through 
the tail of variants has not been explored in depth.  To assess the potential 
phosphorylation of MUC1 splice variants we performed 2D gel analysis of recombinant 
	 83	
X, Y, and SV3 splice variants expressed in HPNE cells (Figure 3.6A).  Western blots of 
the different isoforms show distinct changes in molecular weight for each isoform.  
HPNE-mock tranfected cells showed no specific bands.  Similar to the standard form of 
MUC1, we observed significant deviations to the left of the predicted isoelectric (Figure 
3.6B), suggesting that these MUC1 splice variants can be extensively phosphorylated 




 The transmembrane mucin MUC1 plays a critical role in tumorigenesis through 
the integration of microenvironmental signals and induction of downstream signaling 
cascades to promote cellular responses and adaptation to changes in the extracellular 
microenvironment [26, 43, 81, 83].  We propose that MUC1CT serves as a node to 
integrate morphogenetic signals from a number of diverse networks, in part through its 
capacity to receive multiple differential phosphorylation events.  A number of studies 
have demonstrated that phosphorylation of specific residues in the MUC1 cytoplasmic 
tail are critical to drive its association with signaling factors and transcription factors; 
however, until this report, no studies have evaluated the global phosphorylation status of 
MUC1 [77, 100, 105, 274].  The studies reported here demonstrate that MUC1 exhibits a 
wide array of modifications, including potentially 10 or more phosphorylation events 
within the cytoplasmic tail.  The fact that many of these modifications occur within the 
normal pancreas support the hypothesis that phosphorylation of MUC1 contributes to 
normal signaling in cells, and the finding that this pattern is significantly altered in cancer 
supports the hypothesis that this biological process is co-opted and modified by 
malignant processes in tumor cells. 
	 84	
Most studies have focused on tyrosine phosphorylation of the MUC1CT as a 
major player in MUC1 signaling. Our results show that tyrosine phosphorylation is 
prominent in normal and malignant pancreatic cells; however, treatment with tyrosine 
phosphatase does not remove all modifications, suggesting that a number of serine and 
threonine residues are also phosphorylated.  Preliminary western blot analysis of MUC1 
using phosphospecific antibodies support this hypothesis, though the absolute specificity 
of these antibodies has not been extensively validated.  Interestingly, we found 
significant alterations in the global patterns of phosphorylation by stimulating cells with 
different growth factors, supporting the concept that MUC1 contributes to the integration 
and relay of information about the cytokine status and other factors from surrounding 
environment.  Malignant transformation also results in hyperphosphorylation of the 
cytoplasmic tail, suggesting alterations in signaling pathways during the progression to 
malignancy.  Based on these results, it is likely that the combinatorial pattern of the 
phosphorylated residues is critical for initiating or regulating distinct downstream 
responses.  With the 22 potential sites of phosphorylation, there are more than 
2,000,000 potential phosphorylation patterns, allowing for specific integration of multiple 
signals. 
 We also explored potential modifications other than phosphorylation of the 
cytoplasmic tail.  Previous studies have shown that MUC1 contains a consensus site for 
N-linked glycosylation within the C-terminal subunit, which appears to be N-glycosylated 
[270].  We confirmed this finding in our studies and provide evidence that this form of 
MUC1 can traffic to the nucleus.  Similar studies have shown this effect with β-
dystroglycan, which has a general structure similar to MUC1 [271].  While these studies 
are preliminary and perhaps controversial, the N-glycosylation of MUC1 has been 
reported to regulate its interaction with EGFR [270, 275]. Association of MUC1 and 
EGFR has also been shown to promote its nuclear translocation, suggesting the 
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possibility that these signaling complexes are transported via an endosomal mechanism 
that would allow translocation of both extracellular and intracellular portions of 
MUC1.CT.  Further studies using additional methods of distinguishing protein trafficking 
and improved methods of cellular fractionation will help to address these questions. 
 We and others have found that the C-terminal portion of MUC1 exists as at least 
3 distinct forms.  While we have postulated that two of these forms are full-length 
MUC1.CT either with or without N-glycosylation, to date the smallest form seen 
commonly by gel electrophoresis has not been identified.  We tested the hypothesis that 
these forms were the result of proteolytic cleavage by the TACE protease, but found no 
effect using a specific inhibitor, suggesting that this smaller form may result from 
cleavage from an unidentified protease or may represent a distinct variant. Preliminary 
biochemical studies of recombinant MUC1.CT raise the possibility that this smaller form 
may be the result of a self-cleavage event involving nucleophilic reactions of cysteine 
residues; however, validation of this hypothesis requires further study.  These in vitro 
studies also suggest that MUC1 can readily exist as a dimer, whether this occurs in vivo 
remains controversial.  Use of cysteine mutants may help to validate these studies, 
though serine residues can engage in intein cleavages as well.  Mass-spectrometry 
identification of the fragment may assist in the identification of critical residues and 
determination of whether any excision of internal residues actually occurs.   
 Interestingly, 2D gel analysis of known MUC1 splice variants showed extensive 
phosphorylation similar to canonical MUC1.  As these variants exhibit alterations in the 
extracellular domains, they may propagate signals differently than full-length MUC1.  
This may also account for the diverse phenotypes associated with MUC1 expression. 
These findings also require additional study.  
 The studies reported in this chapter suggest that the C-terminal subunit of MUC1 
is a dynamic structure, driving downstream signaling in part by conducting and 
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integrating signals from growth factor receptors and other factors in the surrounding 
environment.  Future studies examining the specific residues that are phosphorylated 
under given conditions should provide further insight into the specific nature and 
integration of these signals.  For example, some phosphorylation events may require 
previous phosphorylation to create docking sites for other kinases, which may contribute 
to our observation of widely different patterns of phosphorylation.  Better understanding 
of how these processes occur will allow for potential targeting of specific partner 
interaction sites within the cytoplasmic tail to preferentially impede certain signaling 
networks that may be activated in pancreatic cancer.  
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Figure 3.1:  MUC1.CT is Extenstively Phosphorylated 
A) Sequence of the 158 MUC1.CT.  Extracellular, transmembrane, and cytoplasmic tail 
domains are highlighted in each box.  Consensus N-glycosylation site and potential 
phosphorylation sites(*) are also highlighted. B) 2D gel western blot analysis of 
MUC1.CT in normal mouse pancreas and KPC tumor.  For each experiment 175 µg of 
protein lysate were used.  Isoelectric point is mapped below, as well as a prediction of 
isoelectric point for each phosphorylation event.  Treatment of samples with tyrosine 
phosphatase results in shift towards predicted isoelectric point.  These studies were 
performed on multiple, independent samples. C) Western blot analysis of MUC1.CT 
using phosphospecific antibodies against the cytoplasmic tail.  Each epitope is 
highlighted below the blot with the Red residue indicating the site of phosphorylation.  
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Figure 3.2:  Different Stimuli Induce Different Phosphorylation Patterns on MUC1 
Panc1.MUC1-HA cells were serum starved for 24 hours prior to stimulation with either 
100 ng/ml EGF or 10% FBS containing media for 30 minutes.  Cells were lysed and 
analyzed by 2D gel electrophoresis followed by western blot analysis for MUC1 
expression.  Each was sample was prepared identically with 175 µg loaded on the gel.  
Blots were scanned at the same time to control for exposure. EGF stimulation caused a 
specific hyperphosphorylated shift to very low pH range, whereas FBS stimulation 
resulted in a wide range of phosphorylation patterns spread out over the entire 3-10 pH 

















Figure 3.3:  N-Glycosylated MUC1 is Present in the Nucleus 
A) Western blot analysis of MUC1.CT in normal mouse pancreas with or without 
PNGase F treatment.  Samples were prepared identically and split prior to treatment to 
yield two equal concentrations for the gel.  With treatment a shift in molecular weight is 
observed corresponding to loss of N-glycosylation.  B) Western blot of S2013.Neo and 
MIF cytoplasmic and nuclear fractions for expression of MUC1.  MUC1 is present in both 
the cytoplasmic and nuclear fractions and exists as all 3 species we commonly observe.  
GAPDH was used as a loading control for the cytoplasmic fraction C) Western blot 
analysis of nuclear MUC1 following treatment with PNGase F.  The shift in molecular 
weight indicates a loss of N-glycosylation.  H2B serves as the loading control.  All 
western blots were repeated multiple times to ensure reproducibility.  For all western 

















































Figure 3.4:  MUC1.CT Processing is not Impacted by TACE Inhibition 
Western blot analysis of MUC1 expression in S2013.MIF cells following treatment with 
TAPI-2 over 12 or 24 hours.  30 µg of protein lysate was loaded for each sample.  No 
substantial changes were observed in any of the products detected by CT2.  β-actin 
serves as a loading control. 
  













Figure 3.5:  Putative In Vitro Self-Cleavage of MUC1.CT 
A) General schematic of the chemical processes involved in intein self-cleavage.  Initial 
steps involve nucleophilic attack typically involving cysteine and serine residues.  These 
steps are followed by rearrangements that result in excision of the intein and joining of 
the two-extein portions.  These reactions can be catalyzed in vitro through addition of 
reducing agents.  B) Multiple preparations of recombinant His-tagged MUC1.CT (158 
amino acids) were isolated from C41 or C43 E.coli using Nickel affinity column and 
analyzed by western blot analysis under non-reducing or reducing conditions.  Non-
reducing conditions show potential dimerization of monomeric MUC1, reduction causes 
loss of these high molecular weight forms and formation of smaller molecular weight 












































Figure 3.6:  MUC1 Splice Variants are Extensively Phosphorylated 
A) Exon map showing the alternative splicing of MUC1/X, MUC1/SV3, and MUC1/Y.  All 
three of these variants retain the cytoplasmic tail and are detectable using the CT2 
antibody.  MUC1/Y does not undergo SEA cleavage and thus is larger than MUC1/X.  
MUC1/SV3 lacks all of exon 4 and is the smaller than both X and Y B) 2D gel analysis 
was performed using HPNE cells transfected with specific MUC1 splice variants.  All 
gels contained 175 µg of protein lysate.  The MUC1 antibody CT2 was used for 
detection.  The variants did exhibit slightly higher than predicted molecular weight and 
the smear of higher weight forms suggests that these variants may be glycosylated.  
However, each form did run according to its relative size as compared to the other 
variants.  These variants all showed significant deviations to the left off the predicted 
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1. Key Findings 
• Expression of MUC1 drives increased expression and activity of c-Jun 
• MUC1 promotes association of c-Jun and FRA-1, likely in an ERK dependent 
manner 
• FRA-1 promotes migration, invasion, and overall tumor growth in pancreatic 
cancer cells 
• Expression of FRA-1 is increased in clinical specimens of pancreatic ductal 
adenocarcinoma 
• Expression of FRA-1 correlates with expression of pro-EMT genes in a subset of 
clinical specimens 






Pancreatic ductal adenocarcinoma (PDAC) is a prominent cause of cancer 
related deaths worldwide.  Despite recent advances in therapeutic treatment, the 
prognosis for patients remains relatively unchanged, with a median survival of about 6 
months and a 5-year survival of only 6% [1].  Several factors contribute to the poor 
outcome of pancreatic cancer, including difficulties in early diagnosis and the propensity 
of the cancer to metastasize to distant sites early in progression [1, 276].  As such, there 
is a vital need for improved understanding of the mechanisms by which pancreatic 
cancer cells disseminate throughout the body and potential ways to specifically target 
these metastatic cells.  MUC1, a member of the mucin family of glycoproteins that is 
commonly overexpressed and aberrantly glycosylated in pancreatic cancer [277] is 
known to modulate the invasive and metastatic potential of cancer cells.  MUC1 acts by 
influencing the balance of adhesive and anti-adhesive properties, and by engaging in 
morphogenetic signaling that communicates information about structural and 
microenvironmental conditions at the cell surface to the nucleus in a manner that alters 
gene expression [20]. MUC1 exists at the cell surface as a heterodimer comprised of a 
large N-terminal extracellular mucin domain that is non-covalently associated with a C-
terminal domain containing a short extracellular domain, transmembrane region, and a 
cytoplasmic tail [19].  The cytoplasmic tail is differentially phosphorylated by different 
receptor tyrosine kinases and serine and threonine kinases in response to cytokine 
stimulation, physical interactions with counter-receptors, or other factors, and acts as a 
relay of signals from the cell surface to the nucleus [19, 20, 26]. In cancer, MUC1 
potentiates oncogenic signaling through downstream effectors [26] and acts as a 
transcriptional co-regulator in conjunction with transcription factors such as p53, β-
catenin, and c-Jun [26, 77, 102].  This wide range of interaction partners allows MUC1 to 
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act as a signaling hub, integrating signals from cytokine receptor status, cellular 
structure, and other microenviromental conditions to alter cellular behavior.  Among 
these, are the capacity to influence migration and invasion potential [278-280].  
One critical transcription complex impacted by MUC1 is activator protein 1 (AP-
1), a transcription factor comprised of Jun and Fos proteins that were among the first 
oncogenic proteins discovered [125, 173].  The Jun family of proteins includes c-Jun, 
JunB, and JunD, and the Fos family consists of c-Fos, FosB, FRA-1, and FRA-2 [126].  
Jun and Fos proteins exhibit varying degrees of transforming effects on cells, and the 
function of these proteins is dependent on the formation of specific dimers. Jun proteins 
can homodimerize or form Jun:Fos heterodimers. Dimers that comprise AP-1 
transcription factors can bind to TPA response elements (TRE) within DNA to regulate 
transcription, though the DNA elements bound depend in part on the composition of the 
dimer [123, 126]. The AP-1 regulated targets, matrix metalloproteases 1 (MMP1) and 
connective tissue growth factor (CTGF), are known targets of MUC1’s co-regulatory 
activity [77, 100], and we have previously shown that MUC1 over-expression decreases 
the apparent binding of c-Jun to the CTGF promoter element [100].  However, the 
impact of MUC1 expression on other targets of AP-1 has not been studied and how 
MUC1 mediates the displacement of AP-1 from specific promotes remains unknown.  
Based on the capacity of different AP-1 dimers to bind unique promoter elements, we 
hypothesized that MUC1 may alter the composition of the AP-1 dimer as a result of 
integrating oncogenic signaling events to regulate expression of genes associated with 
migration and invasion. 
  In this chapter, we examined how MUC1 modulated AP-1 (c-Jun and FRA-1) 
activity and thereby affected the migratory and invasive properties of pancreatic cancer 
cells.  Our results provide the first evidence that in concert with ERK activation, MUC1 
modifies the formation of AP-1 dimers to preferentially favor c-Jun:FRA-1, which in turn 
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enhances the migration and invasive potential of pancreatic cancer cells in vitro.  We 
show that MUC1 acts as a dominant regulator of FRA-1 function at the CTGF promoter 
and promotes expression of FRA-1 targets involved in migration and invasion.  
Increased expression of FRA-1 mRNA and protein was also observed in clinical PDAC 
samples, and a subset of clinical samples exhibited a FRA-1: EMT gene expression 
signature. Knockdown of FRA-1 significantly impacted tumor growth in vivo, further 
supporting the hypothesis that a novel FRA-1/MUC1 axis contributes to the 




MUC1 increases levels of active c-Jun in tumor cells 
Previous studies demonstrated that MUC1 affects AP-1 regulation of target 
genes in pancreatic cancer cell lines [77, 100].  We initially evaluated the possibility that 
this was due in part to the influence of MUC1 on levels of c-Jun in two MUC1-
overexpressing human pancreatic tumor cell lines, S2013.MIF and Panc1.MUC1, as 
compared to their low-expressing counterparts.  Analysis of total c-Jun in cytoplasmic 
and nuclear fractions showed an increase in total c-Jun within the nucleus of MUC1 
overexpressing cells (Fig. 4.1A & B).  MUC1 expression also increased c-Jun activation 
through phosphorylation at serine 73. Similarly, examination of pancreatic tumor cell 
lines derived from tumors of KPC mice that expressed or were null for Muc1 showed a 
modest increase in total c-Jun within the nucleus when MUC1 was expressed (Fig. 
4.1C).   These observations were confirmed in vivo by analysis of normal mouse 
pancreas and primary pancreatic tumors derived from Muc1 expressing and Muc1-null 
KPC mice, which showed undetectable levels of c-Jun in normal pancreas as compared 
to tumor samples, and that c-Jun expression was further enhanced in tumors expressing 
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Muc1 (Figure 4.1D).  Unlike human tissues, normal mouse pancreas expresses high 
levels of MUC1.  
 
MUC1 promotes the formation of c-Jun:FRA-1 dimers 
We next investigated the hypothesis that MUC1-mediated increases in c-Jun 
levels were due to alterations in dimerization partnerships that are known to stabilize c-
Jun. Previous studies have shown that MUC1 expression leads to displacement of c-Jun 
from promoters [77, 100]. The composition of c-Jun heterodimers is known to impact the 
DNA binding affinity and specificity [197, 198].  We therefore evaluated dimer 
composition by proximity ligation assays to assess the effect of MUC1 on interactions 
between c-Jun and a subset of known dimerization partners (c-Fos, FRA-1, and ATF2), 
which were chosen based on published roles in DNA binding, transformation, or 
metastatic phenotype. Representative images of PLA experiments are shown in Figure 
4.2A. Quantification was performed using the Blobfinder program and results are 
presented as a representation of mean interactions per cell [281], which were further 
subdivided into cytoplasmic and nuclear localization (Figure 4.2B). MUC1 
overexpression did not significantly affect nuclear interactions between c-Jun and ATF2 
or c-Fos; however, c-Jun:FRA-1 interactions were significantly increased (Fig. 4.2C). As 
a secondary validation that MUC1 promoted the association of c-Jun and FRA-1, we 
performed co-immunoprecipitation/western blotting assays to detect stable interactions 
between FRA-1 and c-Jun.  The results showed increased amounts of c-Jun associated 
with FRA-1 in cells over-expressing MUC1 (Figure 4.2D) confirming that MUC1 
promoted the association of c-Jun and FRA-1.  
 
MUC1, ERK, and FRA-1 regulate the migratory and invasive potential of pancreatic 
cancer cells   
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Upregulation of FRA-1 is commonly observed in metastatic breast cancer [186-
188, 282], where it is hypothesized that FRA-1 acts as a driver of invasion and 
metastatic spread of cancer cells.  We sought to determine if FRA-1 played a similar role 
in pancreatic cancer. Given our evidence that FRA-1:c-Jun interactions increased with 
MUC1 overexpression, that FRA-1 can be phosphorylated via ERK, and that MUC1 is 
known to promote signaling through the ERK pathway [81, 126], we investigated the 
effects of MUC1 over-expression on ERK activation. We determined the levels of total 
ERK1/2 and phosphorylated ERK1/2 by western blot analysis on subcellular fractions of 
S2013.Neo and MIF cells.  The results showed increased levels of phosphoERK2 in the 
nucleus of MUC1-overexpressing cells (Figure 4.3A).  Panc1.MUC1 cells also exhibit 
increased ERK2 phosphorylation (Figure 4.4). We confirmed that ERK activation was 
responsible for activation of FRA-1 by treating S2013.Neo and MIF cells with the MEK 
inhibitor U0126.   Western blot analysis indicated that U0126 reduced phosphorylation of 
both ERK and FRA-1 (Figure 4.3B).  
The results of migration and invasion assays using Boyden chamber inserts 
showed that inhibition of ERK signaling by U0126 treatment resulted in approximately 
40% reduction of the number of migrating MUC1 expressing cells, while no effect was 
observed in S2013.Neo cells (Figure 4.3C), supporting the hypothesis of activation of 
FRA-1 enhanced motility in pancreatic cancer cells in concert with MUC1.  Similar 
results were observed for the invasive potential of S2013.MIF cells, indicating increased 
sensitivity to loss of FRA-1 activity (Figure 4.3D).  We confirmed the role of FRA-1 in 
modulating motility by shRNA knock down studies [confirmed by RT-PCR and western 
blot analysis (Figure 4.5A)].  Decreased FRA-1 expression resulted in decreased 
migration and invasion.  Similar to the effect of ERK inhibition, knockdown of FRA-1 
decreased migration and invasion to the greatest degree in cells overexpressing MUC1.  
Conversely, overexpression of FRA-1 (Figure 4.5B) greatly increased the migratory and 
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invasive properties of S2013 cells, whether or not MUC1 was expressed, though cells 
overexpressing MUC1 and FRA-1 showed the highest migratory and invasive activities 
(Figure 4.3C and 4.3D).  Similarly, overexpression of FRA-1 in Panc1.Neo or 
Panc1.MUC1 cells significantly increased both migration and invasion (Figure 4.3E and 
4.3F), whereas knockdown decreased these properties.  Notably, as for S2013 cells, 
these effects were higher in cells expressing higher levels of MUC1. Overexpression of 
FRA-1 also altered the morphology of the cells.  Increased numbers of elongated cells 
with filipodia-like projections were observed in culture (Figure 4.6A-B).  Evaluation of 
these cells for proliferation revealed that at 48 hours, FRA-1 overexpression did not 
impact cellular growth; however, over longer time frames FRA-1 slightly enhanced 
proliferation as assessed by methylene blue growth assay [264] (data not shown). 
 
Loss of FRA-1 expression decreases tumor growth and metastases 
To evaluate the role of FRA-1 in the development and progression of pancreatic 
ductal adenocarcinoma, we performed orthotopic studies evaluating tumor growth of 
S2013.Neo and MIF cells with or without knockdown of FRA-1 expression.  150,000 
cells were injected into the pancreas of nude mice and tumors allowed to progress for 30 
days before mice were sacrificed.  Knockdown of FRA-1 expression resulted in 
significant reduction of primary site growth as assessed by both tumor weight and tumor 
volume in S2013.Neo (Figure 4.7A-B).  This effect was enhanced in S2013.MIF cells 
(Figure 4.7D-E).  Interestingly, one mouse in the S2013.MIF-FRA1 kd group failed to 
develop a palpable tumor, though a small tumor was detected by microscopy.  
Knockdown of FRA-1 also resulted in a reduction in the development of ascites. 
Metastatic spread was assessed by gross analysis of tissues during necropsy 
and confirmed by microscopic examination of collected tissues.  Knockdown of FRA-1 
resulted in a 10-30% reduction in metastases in S2013.Neo, though some sites showed 
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no differences, such as liver metastasis. The effects were less pronounced with high 
levels of MUC1 expression in S2013.MIF (Figure 4.7C & F).   
 
FRA-1 is upregulated in pancreatic cancer  
The role of FRA-1 in pancreatic cancer remains relatively unexplored, though it is 
expressed in numerous pancreatic cancer cell lines [194].  We investigated the 
possibility that FRA-1 contributes in vivo to pancreatic cancer progression by evaluating 
gene expression of FOSL1, which encodes FRA-1, in PDAC samples.  Our initial 
analysis included evaluation of the GEO database for microarray expression data of 
pancreatic ductal adenocarcinoma samples that were compared to normal pancreatic 
tissues.  Using the data series of GSE16515, consisting of 52 samples (36 tumors and 
16 normal samples), we evaluated the gene expression levels of FRA-1 [283, 284].  
Analysis of relative expression levels of FOSL1 using the Generalized Estimating 
Equation (GEE) [285] revealed significant upregulation (p<0.001) in tumors as compared 
to normal samples (Figure 4.8A).  To confirm the results were not skewed by a few 
highly expressing tumors, we compared the 16 tumors that were matched to samples of 
uninvolved pancreas included in this data set. Log2Fold Change was utilized to compare 
overexpression between tumor and normal samples. We observed that 15 of 16 samples 
showed upregulation of FOSL1, and 8 exhibited a change of greater than 2 fold (Figure 
4.8B).   
Our in vitro studies suggest FRA-1 expression is important for invasive potential.  
To assess whether FRA-1 expression changed during the progression of pancreatic 
cancer, we evaluated the data series GSE42952, which includes tumor stage and some 
matched primary and metastatic tumors. FOSL1 expression was plotted for each tumor 
stage identified within the data set, ignoring absent calls (Figure 4.8C) [284, 286].  For 
metastatic sites we differentiated between the identified liver or peritoneal metastatic 
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site.  Late stage tumors showed a slightly higher trend of FOSL1 expression, particularly 
within liver metastases, but the low number of samples prevented us from making 
reliable conclusions based solely on these data.  As a second evaluation, we performed 
immunohistochemistry using tissue microarrays of matched sets of primary and 
metastatic tumors derived from the UNMC Rapid Autopsy Program.  FRA-1 expression 
was examined in primary site tumor, metastatic sites, and normal pancreas from multiple 
patients (Figure 4.9).  A heatmap was generated based upon the intensity of staining 
observed within tumor cells with representative images for scoring presented (Figure 
4.8D).  Most cancer cells exhibited robust nuclear staining, whereas FRA-1 was absent 
in normal pancreas samples; however there were no consistent trends of higher 
expression in metastatic samples in this limited analysis.  Expression of FRA-1 also 
varied in different tumor samples. Thus we conclude that FRA1 is upregulated in some 
but not all pancreatic cancers. 
 
FRA-1 overexpressing tumors exhibit a FRA-1:EMT signature 
Recently a FRA-1:EMT signature has been proposed for colorectal cancer cells 
overexpressing a flagged FRA-1 construct [170]. Eight genes identified as regulated by 
FRA-1 were found to represent part of an Epithelial to Mesenchymal Transition (EMT) 
associated signature: VIM, FN1, FOSL1, ZEB1, SNAI2, AXL, TGFB2, and SMAD3.  We 
chose to examine gene expression of 6 of these genes (FN1, ZEB1, SNAI2, AXL, 
TGFB2, and SMAD3) in PDAC samples. The GSE16515 PDAC data set was analyzed 
for a similar signature. We evaluated paired samples that overexpressed FOSL1 at least 
two-fold, which were predicted to exhibit a FRA-1 associated phenotype [283].  
Calculation of Log2Fold Change for each paired set of tumor and normal samples for 
these targets (Figure 4.10A-F) showed a substantial correlation between FRA-1 
expression and upregulation of these EMT signature mRNAs.  5 of the 6 targets (FN1, 
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ZEB1, SNAI2, AXL, and SMAD3) were upregulated in at least 60% of the tumors with 
high FRA-1 expression; however TGFB2 showed no consistent trend.  Tumor samples 
5, 8, 11, 13, and 15 were most consistent with the predicted FRA-1 signature, mirroring 
the predicted trend 100% of the time for genes other than TGFB2. These results support 
the hypothesis that pancreatic cancer exhibits a FRA-1 driven EMT signature, though 
only within a subset of cases. 
 To examine whether protein expression of these genes correlated with FRA-1 in 
patient samples, we performed IHC for Slug (SNAI2) and ZEB1 on matched sets from 
our rapid autopsy program (Figures 4.11 & 4.12).  Slug was observed in most samples, 
though it was absent in a FRA-1 negative tumor.  ZEB1 was absent in most samples, but 
present in a few tumors highly expressing FRA-1.  A heatmap representing the IHC 
pattern was generated using R (Figure 4.13). These results suggested that even though 
there were effects on mRNA levels, there was not a direct correlation between 
expression of FRA-1 and the protein products of its target genes Slug and ZEB1 in 
clinical samples, demonstrating that factors other than mRNA levels influence steady 
state protein levels of these proteins.  
 
MUC1 regulates expression of FRA-1:EMT gene targets 
 As previous studies have demonstrated the capacity of MUC1 to regulate 
expression of MMP1 and CTGF, we sought to examine how the interplay of MUC1 and 
FRA-1 impacted expression of these genes[77, 287].  We performed RT-PCR analyses 
of our S2013.Neo, S2013.MIF, Panc1.Neo, and Panc1.MUC1 cell lines in conjunction 
with FRA-1 overexpression or knockdown to examine expression of MMP1 and CTGF.  
Expression of FOSL1 was used as a positive control to confirm overexpression or 
knockdown of FRA-1.  Results indicated that increased MUC1 expression dramatically 
impacts expression of MMP1 and CTGF in S2013 cells.  Overexpression or knockdown 
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of FRA-1 did not reverse these effects, indicating a dominance of MUC1 effects at these 
sites, whereas loss of FRA-1 in S2013.Neo resulted in CTGF expression comparable to 
that observed in S2013.MIF (Figure 4.14A).  These results were more modest in Panc1 
cells and reflect a less robust impact of MUC1 on expression of these targets in this cell 
line (Figure 4.14B). 
 To examine whether MUC1 impacted expression of FRA-1:EMT genes, we 
performed additional RT-PCR studies examining expression of SNAI2, ZEB1, TGFB2, 
AXL, SMAD3, and FN1.  Expression of MUC1 in S2013 cells caused significant 
upregulation of many of the FRA-1:EMT genes, including SNAI2, ZEB1, AXL, and FN1.  
Loss of FRA-1 caused significant reduction of these genes to levels comparable to the 
S2013.Neo cell line.  The impact of FRA-1 knockdown in the Neo cell line was relatively 
modest on most FRA-1:EMT genes (Figure 4.14C).  Once again these effects were less 





That MUC1 affects gene expression is well established [80, 89, 103, 288]; 
however, the mechanism by which MUC1 regulates transcription and affects tumor 
progression is not fully understood. MUC1.CT is known to interact with a wide range of 
transcription factors including p53, β-catenin, c-Jun, and others [77, 100, 102]. Previous 
studies have shown that MUC1 displaces c-Jun from promoters of known target genes; 
the data presented here demonstrates this effect is not the result of decreasing the 
levels of c-Jun within the cell.  Rather, our results indicate that high levels of MUC1 alter 
the AP-1 transcriptome in part by increasing steady state levels of c-Jun protein.  We 
went on to demonstrate that this stabilization of c-Jun results in enhanced association 
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with FRA-1 in cells expressing high levels of MUC1, suggesting that MUC1 alters the 
stoichiometry of AP1 protein complexes, which in turn modifies transcriptional activity 
(Figure 4.15).   
We found that MUC1 acts as a dominant regulator of FRA-1 activity that in turn 
modulates expression of CTGF and MMP1.  Additionally, MUC1 upregulated expression 
of several genes associated with FRA-1 mediated EMT.  Steady state mRNA levels for 
these genes were reduced upon FRA-1 knockdown. Together, these results suggest that 
MUC1 serves as a co-activator for FRA-1 at many FRA1-EMT sites, whereas it may 
function as a de-repressor of FRA-1 at the CTGF and MMP1 sites.  The results were 
less apparent in Panc1 cells, which may be attributed to differences in context 
dependent constitutive signaling between the S2013 and Panc1 cell lines.  Indeed, the 
impact of MUC1 on the migration and invasion of Panc1 cells was more modest than the 
effects on S2013 cells.  Thus, it is not surprising that expression of genes involved in 
migration and invasion are not substantially altered in the Panc1 cells. 
Consistent with the findings reported here, FRA-1 has been shown to impact 
migration, invasion, and metastasis in a number of different cancers [126, 170, 187, 
188].  In particular, the role of FRA-1 is well characterized in breast cancer, which also 
commonly exhibits MUC1 over-expression and consequent effects on signaling.  Similar 
to breast cancer, FRA-1 enhances the migratory and invasive capacity of pancreatic 
cancer cells.  The finding of a cooperative effect between MUC1 and FRA-1 that resulted 
in substantial increases in migration and invasion addresses in part the finding that these 
factors show differential effects on transcription of different genes. It is likely that one 
function of MUC1 is to integrate morphogenetic and oncogenic signals that arise from 
cell surface structural conditions, cytokine and growth factor stimulation and steady state 
signaling within the cell [19] to help enact programs of transcriptional response to these 
composite sets of stimuli from the cellular microenvironment and internal signaling 
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apparatus.  Programs of cellular activity (e.g. EMT, cell migration, cell division, other 
cellular functions) require differential transcriptional responses (up-regulation and down-
regulation of different sets of genes), and so it is not surprising that an integrator of 
signaling such as MUC1 would act as both a co-activator and a co-repressor.  For 
results examined here, inhibiting ERK activation or knocking down expression of FRA-1 
produced similar effects in MUC1 expressing cells, which supports the hypothesis that 
MUC1 integrates ERK signaling with morphometric signals related to motility and 
invasion.  Furthermore, we demonstrated that MUC1 enhanced steady state ERK 
activation in pancreatic cancer cells, further supporting the link between ERK activation 
and the functional activity of MUC1 and FRA-1. Previous studies have also 
demonstrated the capacity for MUC1 to promote ERK mediated signaling, however, 
these studies did not evaluate the impact on downstream transcriptional machinery[81, 
86]. These results serve as the first reported evidence of cooperative signaling between 
MUC1 and FRA-1.  This finding could have important implications not only in pancreatic 
cancer, but also in other cancers with aberrant expression of cell surface mucin proteins 
that engage in signal transduction [19].   
Despite the known synergy between AP-1 and oncogenic Ras, few studies have 
examined the expression of AP-1 proteins in pancreatic cancer, which contains K-Ras 
mutations in a vast majority of cases [128, 287].  Our analysis of data from the GEO 
database suggested that FRA-1 is transcriptionally upregulated during the progression 
from normal to cancerous pancreatic tissue and FRA-1 mRNA may also be upregulated 
as the tumor progresses to metastasis.  Immunohistochemistry supported these 
analyses in part, as pancreatic tumors exhibited robust nuclear staining for FRA-1 and 
expression was retained in liver metastases.  FRA-1 staining was absent in samples of 
normal pancreas.  A set of FRA-1 target genes identified in studies of colorectal cancer 
studies was confirmed here for pancreatic cancer.  Recently, it has been proposed that 
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pancreatic cancer consists of 4 distinct subtypes based on genomic analyses [18].  
Interestingly, the squamous subtype of pancreatic cancer proposed exhibits high 
expression of FOSL1, TGFB2, SNAI2, and FN1; all genes we’ve studied within the 
FRA1:EMT phenotype.  This suggests that our proposed FRA1:EMT subset and the 
squamous subtype of pancreatic cancer may be the same group. Immunohistochemistry 
analysis of clinical samples obtained at autopsy provided additional support for the 
hypothesis that FRA-1 was associated with expression of these genes; however, it was 
also apparent that the levels of expression of proteins encoded by the target genes are 
influenced by other factors. Future studies in which the tumors can be stratified 
according to the recently identified subtypes may allow for easier correlations to be 
drawn. Additionally, the dependence of FRA-1 activity on ERK activation suggests that 
tumors (such as pancreatic cancer) bearing activating mutations with the Ras-Raf-MEK-
ERK cascade are likely to exhibit FRA-1 based effects. 
Our results support the hypothesis that FRA-1 contributes significantly to 
metastasis of pancreatic cancer, at least within a subset of cases and also plays an 
important role in overall tumor progression.  Reduction of FRA-1 expression by as little 
as 2-3 fold produced significant reductions in primary site tumor growth in an orthotopic 
model of pancreatic cancer.  Metastases were also reduced, though they were not 
completely inhibited. Recent studies have highlighted a potential role for FRA-1 in 
anchorage independent growth [289].  Other studies have highlighted the importance of 
FRA-1 in promoting YAP driven oncogenesis [290], which is important in the progression 
of pancreatic cancer.  These results suggest FRA-1 may be a viable target to inhibit the 
growth and dissemination of pancreatic cancer cells.  To date no specific inhibitors to 
FRA-1 have been characterized, though various inhibitors such as bromodomain 
inhibitors impact FRA-1 expression [289, 291].  As FRA-1 exhibited a number of effects 
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independent of MUC1, future studies focused on FRA-1 alone may provide further 
insight into the possibility of targeting FRA-1.   
In conclusion, our work presents the first evidence that MUC1 can function by 
altering the composition of AP-1 protein complexes involved in transcriptional regulation.  
This function explains some of the effects of MUC1 on the expression of genes involved 
in migration and invasion, particularly those that are known targets of FRA-1.  We further 
highlight the functional role of these changes as drivers of metastatic and invasive 
potential in pancreatic cancer cells.  Given that 90% of pancreatic cancer patients exhibit 
metastatic spread at diagnosis, the mechanisms behind the early dissemination of 
pancreatic cancer cells need further study [1].  Whereas the mechanism identified in this 
manuscript identifies aspects of the biology of MUC1 in modulating transcriptional 
effects, our in vivo and in vitro studies suggest FRA-1 can independently contribute to 
effects on tumor progression.  Additional study of FRA-1 in pancreatic tumor specimens 
is warranted, as is further study of the specific and redundant functions of c-Jun 
heterodimers in pancreatic cancer.  Future studies should also be undertaken to identify 








Figure 4.1:  MUC1 Increases Expression of c-Jun Protein 
A-B) Cytoplasmic and nuclear fractions of S2013.Neo and MIF cells were western 
blotted for c-Jun, phosphoJun, and MUC1; H2B blotting was evaluated for normalization 
and purity assessment. C) Cytoplasmic and nuclear fractions of cell lines established 
from the tumors of KPC mice that either expressed (MUC1 WT) or lacked MUC1 (MUC1 
KO) were blotted for c-Jun and MUC1 expression with H2B used for normalization and 
purity assessment. D) Whole cell lysates prepared from normal mouse pancreas and 
tumors derived from KPC mice (either MUC1 WT or KO) and were blotted for expression 
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Figure 4.2:  MUC1 Enhances the Interaction of c-Jun and FRA-1 in Pancreatic 
Cancer Cells 
A) Proximity ligation assay examining interactions of c-Jun with the proteins ATF2, c-
Fos, and FRA-1 in S2013.Neo and MIF cells.  Experiments were performed in four 
independent assays; with multiple fields were quantified for each experiment.  
Representative fields are shown and red dots indicate protein-protein interaction.  B) 
Quantification of interactions between c-Jun and associated partners.  Quantification 
was performed using the Blobfinder program and results presented as the average 
number of interactions per cell±SEM.   Significance was assessed using Student’s t-test 
p<0.05 was considered significant.  C) Comparison of the nuclear interactions of c-Jun 
and the associated proteins in S2013.Neo and MIF cells.  Results represent the 
percentage of nuclear interactions/ total interactions±SEM.  Significance was assessed 
with Student’s t-test D)  FRA-1 was immunoprecipitated from Neo and MUC1 
overexpressing cell lines.  The association of FRA-1 and c-Jun was then assessed by 
western blot analysis of co-immunoprecipitated c-Jun.  Levels of c-Jun were normalized 
based upon amount of FRA-1 pulled down and compared between Neo and MUC1 cell 




















































































































































Figure 4.3:  ERK Activity and FRA-1 Drive Invasion and Migration of Pancreatic 
Cancer Cells 
A) Cytoplasmic and nuclear fractions were isolated from S2013.Neo and MIF cells and 
western blot analysis performed for total ERK1/2, phosphoERK1/2, and MUC1.  H2B 
was used for normalization and purity assessment.  Densitometry values are shown 
below the figures.  B) S2013.Neo and MIF cells were serum starved for 24 hours, 
treated with the MEK inhibitor U0126 or DMSO control for 2 hours, then stimulated with 
10% FBS containing media to induce ERK activation. Western blots for phosphoERK1/2 
and phosphoFRA-1.  C-F) Effects of inhibiting ERK Signaling (U0126), knocking down 
FRA1 mRNA, or overexpressing FRA1 mRNA on Migration (C & E) and Invasion (D & F) 























































































































































































































Figure 4.4:  ERK Activity is Increased in Panc1.MUC1 Cells 
A) Western blot analysis evaluating the expression of total ERK1/2 and phosphoERK1/2 
in Panc1 cells.  Relative amounts were determined by densitometry using H2B as a 
loading control.  Calculations were performed for each localization and are for ERK2 
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Figure 4.5:  Validation of FRA-1 Knockdown and Overexpression Cell Lines 
A) Characterization of FRA-1 knockdown cell lines.  FRA-1 experession was knocked 
down by shRNA and expression of FRA-1 was assessed by both western blot analysis 
and RT-PCR.  Reduction in FRA-1 expression was similar between the Neo and MUC1 
expressing counterparts.  B) Characterization of FRA-1 levels following stable 
overexpression of HA-tagged FRA-1 construct. Lysates were probed for FRA-1 
expression using an anti-HA antibody and MUC1.  Actin served as a loading control.  
Both the Panc1 and S2013 cell lines express similar levels of FRA-1 independent of 


















































































































































































Figure 4.6:  FRA-1 Expression Alters Cellular Morphology 
Images of cancer cells with and without FRA-1 overexpression were taken using an 
EVOS digital microscope.  Cells were than examined for changes in cellular morphology.  
Both Panc1 (A) and S2013 cells (B) exhibit increased numbers of cells with cellular 












Figure 4.7:  Knockdown of FRA-1 Decreases Tumor Growth and Metastasis 
A-B) Tumor weight and Tumor volume were plotted for mice injected with S2013.Neo 
(n=12) or S2013.Neo-FRA1 kd (n=12) cells.  The mean was calculated ± SD.  
Knockdown of FRA-1 resulted in significant reduction of both weight and volume 
(Bonferroni adjusted p-values following ANOVA and Bonferroni method for multiple 
comparisons).  C) Presence of ascites or metastasis was assessed for each individual 
mouse and the fraction of total mice for each condition was calculated.  D-E) Tumor 
weight and volume plotted for mice injected with S2013.MIF (n=13) or S2013.MIF-FRA1 
kd (n=13) cells.  The mean was calculated ± SD (Bonferroni adjusted p-values following 
ANOVA and Bonferroni method for multiple comparisons).  F) Presence of ascites or 










































































































Figure 4.8:  FOSL1 is Overexpressed in Pancreatic Ductal Adenocarcinoma 
Samples 
A) Gene expression data from the NCBI GEO dataset GSE16515 was analyzed for 
expression of FOSL1 (FRA1) using microarray expression values.  Expression values 
from tumor and normal samples are presented.  Statistical comparison of the groups 
was performed using the Generalized Estimating Equation (GEE) to account for the 
paired tumor and normal samples.  Analysis revealed a significant increase in FOSL1 
expression in the tumor group (p<0.001) as compared to normal.  B) To confirm tumor 
samples upregulated FOSL1 16 paired tumor and normal samples were compared.  The 
log2Fold Change in gene expression for tumor/normal was calculated and plotted.  15 of 
16 samples show upregulation in the tumor.  8 of 16 showed an upregulation greater 
then 2 fold (log2Fold Change >1) C) Gene expression data for staged pancreatic tumor 
specimens was mined using the NCBI GEO dataset GSE42952.  The expression of 
FOSL1 was plotted for each specified staging with absent calls ignored.  D) 
Immunohistochemistry was performed to evaluate the protein expression of FRA-1 in 
pancreatic cancer.  A heatmap representing relative staining for FRA-1 was generated 
using R.  Scoring was based upon intensity of stain observed only within tumor cells.  

































































































































































































































































































































































































































































































































































































































































































































Figure 4.9:  Analysis of FRA-1 Expression in PDAC Samples 
Tissue microarrays were stained for expression of FRA-1.  Samples were collected from 
the UNMC Rapid Autopsy Program.  Each number represents an individual patient.  
Primary and metastatic sites were stained and compared to normal pancreas.  
Metastatic sites were collected from the liver unless otherwise indicated. 
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Figure 4.10:  Pancreatic Cancer Samples Exhibit Similar FRA1:EMT Signature as 
Colorectal Cancer Cells 
A-F) Gene expression data from the NCBI GEO dataset GSE16515 for 6 FRA1:EMT 
signature genes (FN1, ZEB1, SNAI2, AXL, TGFB2, SMAD3) were plotted.  For genes 
with multiple probes the average of all probes was used.  Only tumors showing >2-fold 
upregulation of FRA-1 were used for this analysis.  
  

















































































































































Figure 4.11:  Analysis of Slug Expression in PDAC 
Tissue microarrays were stained for expression of Slug.  Samples were collected from 
the UNMC Rapid Autopsy Program.  Each number represents an individual patient.  
Primary and metastatic sites were stained and compared to normal pancreas.  
Metastatic sites were collected from the liver unless otherwise indicated. 
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Figure 4.12:  Analysis of ZEB1 Expression in PDAC Samples 
Tissue microarrays were stained for expression of ZEB1.  Samples were collected from 
the UNMC Rapid Autopsy Program.  Each number represents an individual patient.  
Primary and metastatic sites were stained and compared to normal pancreas.  
Metastatic sites were collected from the liver unless otherwise indicated. 
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Figure 4.13:  Heatmap of Immunohistochemistry Studies 
Heatmaps were generated based upon staining of FRA-1, Slug, and ZEB1 in  
pancreatic cancer samples.  Scoring was based upon relative intensity of staining and 
each TMA was scored independently to avoid bias based upon antibody differences.  

















































































































































Figure 4.14:  MUC1 Regulates Specific AP-1 and FRA-1 Targets 
A-B) RT-PCR studies were performed to examine the impact of FRA-1 on the MUC1 
regulated genes MMP1 and CTGF.  FOSL1 expression was measured to confirm 
overexpression or knockdown of FRA-1.  Results were analyzed by 2-way ANOVA and 
p-values represent comparison of FRA-1 overexpression and knockdown lines to 
parental unless otherwise indicated by lines.  MUC1 expression caused significant 
alterations to expression of MMP1 and CTGF.  Alteration of FRA-1 expression had no 
impact on expression in S2013.MIF, but significantly altered expression of these genes 
in S2013.Neo   C-D) Additional RT-PCR studies were performed to examine the impact 
of MUC1 and FRA-1 on expression of putative FRA1:EMT genes.  Results were 
analyzed by 2-way ANOVA for multiple comparisons and p-values indicate significant 
differences between parental and FRA-1 knockdown cell lines unless otherwise 
indicated by lines.  In S2013 cells (C) MUC1 caused significant increases in expression 
of these genes.  Loss of FRA-1 abrogated this effect and restored expression to levels 
similar to S2013.Neo cells.  Similar effects were observed for the regulation of AXL in 























































































































































































































































Figure 4.15:  MUC1 and ERK Cooperate to Drive Association of c-Jun and FRA-1 
Schematic representation of our proposed mechanism in MUC1 expressing pancreatic 
cancer cells.  Phosphorylation of the MUC1 cytoplasmic tail drives downstream 
activation of ERK, likely involving the association of MUC1 with receptor tyrosine 
kinases.  Increased ERK activity results in phosphorylation of FRA-1 and promotes 
dimerization with c-Jun.  The transcriptional complex is then stabilized and allows for 


















Chapter V:  FRA-1 Knockdown Confers Additive 
Benefits to BET Inhibition 
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1. Key Findings 
• The impact of BET inhibition on the expression of FRA-1 is variable and likely 
depends on multiple factors 
• Overexpression of FRA-1 does not protect cells from growth inhibition with BETi 
• Knockdown of FRA-1 confers additive effects on growth inhibition with BETi 
• Knockdown of FRA-1 does not synergize with G1/G0 arrest induced by BETi 
• Knockdown of FRA-1 results in decreased expression of pro-growth genes and 




   
Fos-related antigen 1 (FRA-1) is a member of the Fos family of proteins [126], 
which together with the Jun family of proteins, comprise the dimeric transcription factor 
AP-1 [121].  Initial discovery of the viral oncoproteins v-Jun and v-Fos highlighted the 
activity of AP-1 in cancer and has led to extensive exploration of this pathway for 
targeted therapy in cancer [121, 292].  The combinatorial diversity of AP-1 that arises 
from its capacity to form 18 potential dimeric combinations has led to the demonstration 
that AP-1 imparts a wide range of effects, including promotion of cellular growth, 
apoptosis, and invasive behavior [121]. These effects are dependent on the composition 
of the dimer and are often cell type dependent [121, 165, 198].  FRA-1 has been 
identified as a significant driver of invasion and metastasis in breast cancer and 
colorectal cancer, however, the impact of FRA-1 on pancreatic cancer remains relatively 
unexplored [170, 186, 188, 189].   
 Pancreatic cancer remains one of the most difficult cancers to treat, with a 5-year 
survival rate hovering around 6-7% [1].  Current therapies are largely ineffective and as 
a result, there is a vital need to identify novel targets.  Recently, we found that FRA-1 
expression is increased in a significant fraction of pancreatic ductal adenocarcinoma 
(PDAC) samples [169].  Enhanced expression of FRA-1 in pancreatic cancer cells 
increased migratory and invasive properties, similar to effects observed in breast cancer 
cells.  Knockdown of FRA-1 diminished these properties and resulted in diminished 
tumor growth and metastasis in vivo.  Additional studies have supported a role for FRA-1 
in the three-dimensional growth of pancreatic cancer cells in collagen [289].  These 
studies suggest that FRA-1 may be a potential therapeutic target in pancreatic cancer. 
 While there are no current therapies directed against FRA-1, treatment of cells 
with inhibitors of bromodomain and extracellular terminal (BET) proteins has shown a 
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propensity to decrease expression of FRA-1 and c-Myc [289, 291].  BET expression is 
deregulated in a host of cancers and there are currently several clinical trials in progress 
examining the efficacy of BET inhibition (BETi).  In pancreatic cancer, BETi has shown 
the ability to inhibit growth both in vitro and in patient-derived xenografts [293].  Despite 
potential effects on FRA-1, most studies of BETi have focused on its effects with c-Myc 
[291, 294-296]. One study in lung cancer showed that overexpression of FRA-1 failed to 
protect cells from BETi [297].  Our previous results implicating FRA1 in pancreatic 
cancer [169] led us to examine how expression of FRA-1 impacted the efficacy of BETi 
on pancreatic cancer, and whether dual inhibition of FRA-1 and BET proteins would 
result in synergistic decreases in tumor growth.  Furthermore, we attempted to confirm 
that BET inhibition caused decreased expression of FRA-1. 
 We found that treatment of pancreatic cancer cell lines with the BET inhibitors 
JQ1 and OTX015 failed to consistently decrease expression of FRA-1 in 2-dimensional 
growth.  Similar to studies in lung cancer, overexpression of FRA-1 did not protect cells 
from BETi.  However, knockdown of FRA-1 in conjunction with BETi resulted in an 
additive decrease in cellular growth, apparently through independent molecular 
mechanisms of action.  We observed no cooperative effects on cell cycle arrest in cells 
treated with BETi and FRA-1 knockdown; however, RNA-seq analysis of FRA-1 
knockdown cells revealed significant alterations in cell growth and survival pathways, 
suggesting that loss of FRA-1 decreases overall cellular viability.  Our results suggest 




BET Inhibition Exhibits Variable Impact on FRA-1 Expression 
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 Previous studies have shown the treatment of cells with BET inhibitors commonly 
results in decreased expression of FRA-1 [289, 291, 298]. To determine if JQ1 or 
OTX015 treatment downregulated FRA-1 in pancreatic cancer cell lines, we treated 
Colo357, AsPC1, Panc1, and S2013 cell lines with increasing concentrations of either 
JQ-1 or OTX015 (50nM to 500nM).  Cells were grown as a monolayer and treated for 48 
hours before lysis.  Western blot analysis of FRA-1 expression showed mixed responses 
to BET inhibition.  Both Colo357 (Figure 5.1A) and AsPC1 (Figure 5.1C) exhibited no 
decrease in expression of FRA-1 in response to either JQ1 or OTX015.  Interestingly, 
AsPC1 showed increased expression of FRA-1 as the dose of BET inhibitor was 
increased. Panc1 (Figure 5.1B) and S2013 (Figure 5.1D) cells showed modest 
decreases in the expression of FRA-1 with higher doses of OTX015, though no 
decrease of expression was observed with JQ-1.  Thus, we conclude that BETi alone 
does not consistently modulate expression of FRA-1 in pancreatic cancer cells. 
 To evaluate the role of FRA-1 expression on the efficacy of BET inhibitors, we 
generated both FRA-1 knockdown and FRA-1 overexpression cell lines using the S2013 
and Panc1 pancreatic cancer cell lines (Figure 5.1E and 5.1F).  Expression of FRA-1 
was assessed by both western blot analysis and RT-PCR analyses to confirm that FRA-
1 was appropriately knocked-down or overexpressed. 
 
Knockdown of FRA-1 Expression Confers Additive Impacts on Cell Growth with 
BET Inhibition 
 Previous studies examining the mechanisms of BET inhibition have focused 
primarily on the role of c-Myc on growth.  Given that recent studies by our lab and others 
have demonstrated that FRA-1 influences pancreatic cancer cell growth both in vitro and 
in vivo, we sought to examine whether knockdown of FRA-1 expression would cooperate 
with, or inhibit effects of BET inhibition. Parental, FRA-1 overexpressing, and FRA-1 
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knockdown cell lines were treated with increasing doses of JQ1, OTX015, or a DMSO 
vehicle control.  Methylene Blue assays were performed to assess cellular proliferation 
over time.  
We found that effects of BET inhibition on cell proliferation were not affected 
synergistically by FRA-1 overexpression or knock-down in both S2013 (Figure 5.2A-C 
and Figure 5.3A-C) and Panc1 (Figure 5.4A-C and Figure 5.5A-C) cells.  This shows that 
FRA-1 does not protect cells from BET inhibition.  Nonetheless, significant inhibition of 
growth was observed in most cell lines at 250nM of either JQ1 or OTX015 after 96 
hours, and loss of FRA-1 expression significantly decreased growth independent of BET 
inhibition for both cell lines in an additive manner.  As a result, the combination of FRA-1 
knockdown and BET inhibition was significantly better then BET inhibition alone (Figures 
5.2-5.5).  This was true for both S2013 and Panc1 cells at virtually every dose of BET 
inhibitor, though 1 µM OTX015 showed no significant difference in Panc1 cells with 
knockdown of FRA-1 (Figure 5H). 
 
Loss of FRA-1 Does Not Synergize with BETi mediated G1 Arrest 
 As loss of FRA-1 alone is sufficient to decrease cellular growth, we sought to 
examine whether the mechanism was independent or synergistic with BETi.  Previous 
studies of FRA-1 have shown that loss of FRA-1 can result in alterations in cyclin 
expression [299-301].  This in turn leads to slower progression through the cell cycle and 
decreased cellular proliferation.  To test whether FRA-1 caused aberrations in cell cycle 
progression, we performed cell cycle analysis on parental and FRA-1 knockdown lines in 
the presence or absence of BET inhibition.  For these studies, the 500 nM concentration 
was chosen based on results showing significant differences in growth between the 
parental and FRA-1 knockdown cell lines.  BET inhibition caused accumulation of cells in 
G1, consistent with the literature [294, 302].  Loss of FRA-1 resulted in accumulation in 
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G2/M in Panc1 cells and accumulation in S phase in S2013 cells, suggesting an affect 
on cell cycle progression; however, we did not observe synergistic accumulation of cells 
in G1/G0 (Figure 5.6A-B). 
 To test whether FRA-1 expression influenced expression of cyclins, we 
performed western blot analysis of lysates from 96-hour treatment time points.  Western 
blots for Cyclin A and Cyclin D showed that FRA-1 loss promoted decreased expression 
in response to BET inhibition in Panc1 cells (Figure 5.6A).  However, these effects were 
not observed in S2013 cells, suggesting that other factors are involved in decreasing 
cellular growth (Figure 5.6B). 
 
Loss of FRA-1 Results in Decreased Cellular Fitness 
 We performed RNA-seq analysis of the S2013.Neo and S2013.plKO FRA1 cell 
lines to identify mechanisms that may explain the decreased cellular proliferation 
observed in FRA-1 knockdown cells.  Differences in gene expression between the cell 
lines were analyzed using QIAGEN’s Ingenuity® Pathway Analysis to identify cellular 
pathways that were altered by decreased FRA-1 expression [265].  Heatmaps generated 
using QIAGEN’s Ingenuity® Pathway Analysis demonstrate the increased expression of 
cell death genes (Figure 5.6C) and decreased expression of proliferative genes (Figure 
5.6D), suggesting that loss of FRA-1 may diminish cellular viability.  Additionally, 
pathways associated with cellular movement and motility were significantly impacted, 
which is consistent with the known role for FRA-1 in the migration and invasion of cells 







 Bromodomain inhibitors have been studied recently as potential therapeutics for 
a wide range of cancers [303-305].  Many of the currently available inhibitors elicit 
cytostatic effects on tumor growth, rather than cytotoxic effects [306, 307].  As such, a 
priority is identifying potential targets that can synergize with BET inhibitors, or in 
combination enhance cytotoxicity.  Previous studies have identified FRA-1 as a factor 
commonly impacted by BET inhibition [289, 291, 298].  In the studies reported here, we 
sought to examine whether targeting FRA-1 would synergize with the BET inhibitors JQ1 
and OTX015.  Whereas previous studies in breast cancer cell lines found that JQ1 
treatment resulted in decreased expression of FRA-1, we found no consistent impact of 
BET inhibition on FRA-1 expression in pancreatic cancer. BET inhibition is known to 
have variable effects with known targets such as Myc, the most characterized target 
[293]. Interestingly, FRA-1 has been shown to control expression of several known Myc 
targets, and in some instances FRA-1 affects expression patterns for genes that may 
compensate for loss or lack of Myc expression [299].  This may explain in part the 
context dependent effects of BET inhibitors. 
 Cells with reduced FRA-1 activity through knockdown or treatment with BET 
inhibitors exhibited a significant reduction in growth as compared to parental lines.  
However, this effect appeared to be additive, as loss of FRA-1 expression alone reduced 
cellular growth, albeit to a lesser extent.  Our finding that overexpression of FRA-1 failed 
to protect pancreatic cancer cells from the growth inhibitory effects of BET inhibitors 
provided additional evidence that BET inhibitors function independently of FRA-1.  This 
is consistent with results reported in lung cancer [297].  BET inhibition is reported to 
induce G1/G0 arrest, which we also observed [306, 307].  Knockdown of FRA-1 failed to 
enhance the arrest induced by either JQ1 or OTX015, further suggesting that oncogenic 
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mechanisms of FRA-1 activity can be independent of BETi.  As well, western blots 
examining cyclin levels failed to identify a consistent mechanism of growth arrest.  For 
Panc1 cells, loss of FRA-1 induced a cooperative reduction of Cyclin A and Cyclin D1 
expression in response to BET inhibition, however, these effects were not observed in 
S2013 cells, suggesting that the growth inhibitory effects of knocking down FRA-1 are 
not due to effects on these cyclins.   
 RNA-seq analysis of the S2013 cell lines suggested that the additive effects of 
FRA-1 knockdown and BET inhibition resulted from reduced expression of pro-growth 
genes and consequent decreases in cellular proliferation.  Previous studies in triple 
negative breast cancer demonstrated that FRA-1 enhanced cellular growth and 
expression of pro-growth genes [185]; however, this has not been previously reported for 
pancreatic cancer.  Interestingly, expression of FRA-1 has been shown to occur in a 
recently identified putative subtype of pancreatic cancer [18].  Taken together, these 
results suggest that FRA-1 may be a viable target in a range of cancers and that 
inhibiting AP-1 complexes may be additive to effects of BET inhibitors.    Unfortunately, 
targeting other AP-1 complexes has proven extremely difficult in the clinical setting [308].  
Recently a selective AP-1 inhibitor (T-5224) demonstrated efficacy in a few preclinical 
models of cancer [309].  Future studies examining the efficacy of this drug in pancreatic 
cancer may provide insight into the utility of broadly targeting AP-1.    
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Figure 5.1:  FRA-1 Exhibits Variable Responses to BET Inhibition 
A) Colo357, B) Panc1, C) AsPC1, and D) S2013 cells were treated with increasing 
doses of the BET inhibitors OTX015 or JQ1 and cell lysates were evaluated for the 
impact on expression of FRA-1.  β-actin was used as a loading control.  Western blots 
were repeated three times to ensure reproducibility.  E) FRA-1 knockdown cell lines 
were evaluated for FRA-1 expression by western blot analysis and RT-PCR analysis.  
Overall gene expression was normalized to 18s rRNA for RT-PCR analysis.  Both Panc1 
and S2013 cell lines showed knockdown of FRA-1 expression.  F) FRA-1 
overexpression cell lines were generated in Panc1 and S2013 cells.  Expression of HA 
tagged FRA-1 was confirmed by western blot analysis for the HA-tag.  Increased 








50 100 250 500
50 100 250 500- - - -








50 100 250 500
50 100 250 500- - - -








50 100 250 500
50 100 250 500- - - -








50 100 250 500
50 100 250 500- - - -




































































































































Figure 5.2:  JQ1 Treatment Results in Additive Decreases in Cell Growth with FRA-
1 Knockdown in S2013 Cells 
A) S2013 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with 
different concentrations of JQ1 or DMSO control.  Cellular growth was measured by 
absorbance at 650 nm with methylene blue assay.  Absorbance was plotted over time to 
generate growth curves and statistical analyses were performed using 2-way ANOVA 
comparing to the control (*p<.05, **p<.01, ***p<0.001).  Absorbance values represent 
average of 6 wells for each cell line to control for variability in cell plating and growth due 
to plate position. D-H)  The growth curves for the parental, HA-FRA1, and FRA-1 
knockdown lines were compared at each individual concentration.  Differences between 
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way 
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001).  Each assay was performed 
multiple times to ensure reproducibility. 
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Figure 5.3:  OTX015 Treatment Results in Additive Decreases in Cell Growth with 
FRA-1 Knockdown in S2013 Cells 
A) S2013 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with 
different concentrations of OTX015 or DMSO control.  Cellular growth was measured by 
absorbance at 650 nm with methylene blue assay.  Absorbance was plotted over time to 
generate growth curves and statistical analyses were performed using 2-way ANOVA 
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent 
average of 6 wells for each cell line to control for variability in cell plating and growth due 
to plate position.  D-H)  The growth curves for the parental, HA-FRA1, and FRA-1 
knockdown lines were compared at each individual concentration.  Differences between 
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way 
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001).  Each assay was performed 
multiple times to ensure reproducibility. 
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Figure 5.4:  JQ1 Treatment Results in Additive Decreases in Cell Growth with FRA-
1 Knockdown in Panc1 Cells 
A) Panc1 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with 
different concentrations of JQ1 or DMSO control.  Cellular growth was measured by 
absorbance at 650 nm with methylene blue assay.  Absorbance was plotted over time to 
generate growth curves and statistical analyses were performed using 2-way ANOVA 
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent 
average of 6 wells for each cell line to control for variability in cell plating and growth due 
to plate position.  D-H)  The growth curves for parental, HA-FRA1, and FRA-1 
knockdown lines were compared at each individual concentration.  Differences between 
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way 
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001).  Each assay was performed 


























Panc1.plKO FRA1 +1uM JQ1





















Panc1.plKO FRA1 +500nM JQ1






















Panc1.plKO FRA1 +250nM JQ1




















Panc1.plKO FRA1 +100nM JQ1
















nm Panc1.Neo ctlPanc1.Neo +50 nM JQ1
Panc1.HA-FRA1 ctl
Panc1.HA-FRA1 +50 nM JQ1
Panc1.plKO FRA1 ctl
Panc1.plKO FRA1 +50nM JQ1















nm Panc1.plKO FRA1 ctlPanc1.plKO FRA1 +50nM JQ1
Panc1.plKO FRA1 +100nM JQ1
Panc1.plKO FRA1 +250nM JQ1
Panc1.plKO FRA1 +500nM JQ1
Panc1.plKO FRA1 +1uM JQ1







































Panc1.Neo +50 nM JQ1
Panc1.Neo +100 nM JQ1
Panc1.Neo +250 nM JQ1
Panc1.Neo +500 nM JQ1
Panc1.Neo +1 uM JQ1






















































































0 24 48 72 96
ns ns *** Neo.Tx vs. plKO.Tx
0 24 48 72 96
ns ns *** Neo.Tx vs. plKO.Tx
0 24 48 72 96
ns ns *** Neo.Tx vs. plKO.Tx****** ****** ******
0 24 48 72 96
ns ns *** Neo.Tx vs. plKO.Tx
0 24 48 72 96
ns ns *** Neo.Tx vs. plKO.Tx***** ***ns
 *** p<0.001 ** p<0.01 * p<0.05
Figure 5.4
	 163	
Figure 5.5:  OTX015 Treatment Results in Additive Decreases in Cell Growth with 
FRA-1 Knockdown in Panc1 Cells 
A) Panc1 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with 
different concentrations of OTX015 or DMSO control.  Cellular growth was measured by 
absorbance at 650 nm with methylene blue assay.  Absorbance was plotted over time to 
generate growth curves and statistical analyses were performed using 2-way ANOVA 
comparing to the control (*p<.05, **p<.01, ***p<0.001).  Absorbance values represent 
average of 6 wells for each cell line to control for variability in cell plating and growth due 
to plate position.  D-H)  The growth curves for the parental, HA-FRA1, and FRA-1 
knockdown lines were compared at each individual concentration.  Differences between 
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way 
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001).  Each assay was performed 
multiple times to ensure reproducibility. 
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Figure 5.6:  Loss of FRA-1 Decreases Cellular Fitness but Fails to Synergize with 
BET Inhibition 
A) Cell cycle analysis of Panc1 or B) S2013 cells with or without FRA-1 knockdown at 
selected time points following treatment with BET inhibitors.  The percentage of cells 
observed within each phase is presented for each time point.  Additionally, western blot 
analysis was performed to examine the impact of FRA-1 expression and BET inhibition 
on the expression of Cyclin A2 and Cyclin D1.  β-actin served as a loading control. C) 
Heatmap generated from Ingenuity® Pathway analysis demonstrating increased 
expression of genes involved in cell death or D) cellular proliferation.  Shading is based 
upon differential Z-score.  E) List of significantly altered pathways between S2013.Neo 
and S2013.plKO FRA-1 cell lines identified using QIAGEN’s Ingenuity® Pathway 
Analysis.  P-values are calculated based on the odds of finding x number of genes 
differentially regulated within the same network. 
  
Panc1.Neo Panc1.plKO FRA1










































































Cell Death and Survival 1.29E-03 - 3.44E-35
Cellular Movement 1.54E-03 - 3.18E-31
Cellular Development 1.43E-03 - 6.63E-28
Cellular Growth and Proliferation 1.43E-03 - 6.63E-28



















Chapter VI:  Impact of p53 Mutation Status on the 




1. Key Findings 
• MUC1 preferentially interacts with the R273H hotspot mutant of p53, as 
compared to wildtype or R175H p53 
• Expression of R273H results in increased expression of CTGF, but wildtype and 
R175H p53 are unable to induce CTGF 
• Expression of p53 under steady state conditions has no impact on the cellular 
growth of Colo357 cells 
• Irradiation of wildtype p53 expressing cells causes growth arrest quicker than 
mutant p53 expressing cells 
• Irradiation induces phosphorylation of wildtype p53 and induction of PUMA, but 
does not result in phosphorylation of mutant p53 
• UV damage induces phosphorylation of wildtype and mutant p53, but this effect 





 The tumor suppressor p53 is mutated in approximately 50-75% of pancreatic 
ductal adenocarcinoma cases [310].  The majority of p53 mutations occur within the 
DNA binding domain of p53 resulting in disruptions to normal DNA binding [311].  As a 
result, therapeutic intervention to restore wildtype p53 function has been extensively 
studied [312].  While it was initially postulated that these mutations resulted in loss of 
p53 function, recent studies have indicated that p53 mutants retain variable DNA binding 
capacity and may exhibit gain-of-function effects [243, 313-317].  Indeed, in the KPC 
pancreatic cancer mouse model, loss of p53 tumors exhibit a distinct phenotype from 
tumors arising from mutant p53 [15].  Other studies have also demonstrated that a p53 
null allele is not equivalent to a mutant allele, further supporting the potential for gain-of-
function effects [239]. 
 The transmembrane glycoprotein MUC1 has been shown to interact with p53 
resulting in alterations to downstream transcriptional targets and changes in promoter 
occupancy [77, 80, 100].  Preliminary data from our laboratory suggest that these 
interactions are determined in part by phosphorylation of specific residues within the 
cytoplasmic tail of MUC1.  How the mutational status of p53 influences these 
interactions has not been explored.  To study this, we designed a doxycycline-inducible 
system to express specific p53 isoforms in pancreatic cancer cells.  We found that the 
hotspot mutant R273H appears to preferentially interact with MUC1, however, both 
wildtype and R175H mutant p53 also interacted with MUC1.  Furthermore, when we 
examined expression of CTGF, a gene previously suggested to be regulated by the 
interaction of p53 and MUC1 at upstream promoter elements [100], we found that 
expression of R273H caused the most robust increase in expression of CTGF as 
compared to wildtype or R175H p53.  We also examined expression of MMP1, which is 
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thought to be downregulated in response to this interaction [77].  We observed that both 
wildtype and R175H caused a modest decrease in expression at low doses; however, 
R273H was unable to decrease MMP1 expression.  These results suggest that the 
mutational status of p53 may influence particular gain-of-function effects on gene 
targets.  Furthermore, some of these effects may be dose dependent on the overall 
levels of p53. 
 Interestingly, p53 expression did not alter the growth kinetics of Colo357 cells as 
assessed by methylene blue assay.  This suggests that under steady state conditions 
these cells have become unresponsive to p53.  However, when we irradiated cells we 
found that wildtype p53 expression caused cells to cease growth sooner than either 
R175H or R273H.  When we examined the response of these cells to irradiation we 
found that wildtype p53 was phosphorylated in response to DNA damage, whereas 
neither mutant was phosphorylated under these conditions.  Furthermore, wildtype p53 
showed induction of the pro-apoptotic protein PUMA.  These results suggest that 




Colo357 Cells Express High Levels of Endogenous MUC1 and no p53 
To identify a suitable cell line for studies involving re-expression of different 
isoforms of p53, we performed western blot analysis of several pancreatic cancer cell 
lines.  In order to minimize complications from variables in MUC1 and p53 expression 
we sought a cell line that expressed endogenous MUC1 and either wildtype or no p53.  
S2013 and Panc1 cells were not usable for these assays due to lack of endogenous 
MUC1 expression and natural expression of mutant p53.  We found that Colo357 
expressed high levels of endogenous MUC1 (Figure 6.1).  Furthermore, while Colo357 
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are proposed to retain wildtype p53 alleles, we observed no p53 expression in these 
cells making them the ideal cell line for our studies [318]. 
 
Designing a Dox-Inducible System for p53 Expression 
As a starting point, we designed 3 distinct p53 constructs; wildtype, R175H, and 
R273H (Figure 6.2A).  The R175H and R273H mutations are both hotspot mutations in 
the DNA binding domain and commonly occur in pancreatic cancer cell lines [319].  
Furthermore, the R175H mutation is orthologous to the R172H mutation that was used in 
generation of the KPC mouse model of pancreatic cancer.  These mutations also 
represent distinct classes of mutants, as R175H disrupts DNA binding by altering the 
structure of p53, whereas the R273H mutation disrupts a residue involved in direct DNA 
binding [311].  We cloned the human wildtype p53 cDNA sequence into the plvx.Tight-
puro vector from Clontech (graciously provided by Dr. Angie Rizzino) and added a triple 
flag sequence to the C-terminus to facilitate detection and isolation.  Site-directed 
mutagenesis was performed to generate mutants and sequencing was used to confirm 
mutations (Figure 6.2B).  To validate the induction of recombinant p53 in transduced 
cells, increasing doses of doxycycline were applied in culture and p53 expression 
assessed by western blot analysis by both a p53 antibody and an antibody against the 
flag sequence (Figure 6.2C).  Dose dependent induction of p53 was observed for all 3 
constructs.  Each cell line exhibited similar levels of p53 expression upon induction. 
 
MUC1 Preferentially Interacts with the R273H Hotspot Mutant 
  To assess how the mutational status of p53 impacts interaction with MUC1, we 
performed reciprocal co-immunoprecipitation assays for both proteins.  Lysates were 
prepared from each cell line and levels of p53 and MUC1 were similar in the sample 
inputs for immunoprecipitation (Figure 6.3A).  Immunoprecipitation of p53 was performed 
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using M2 agarose beads and western blot analysis was performed for both p53 and co-
associated MUC1.  We observed a modest increase in associated MUC1 with the 
R273H mutant; however, this result was confounded by the background signal from 
antibody light chain used in the immunoprecipitation (Figure 6.3B).  The reciprocal 
experiment also showed increased association between MUC1 and R273H, supporting 
the hypothesis that MUC1 shows enhanced interaction with this mutant as compared to 
wild-type and R175H (Figure 6.3C), though there were interactions between MUC1 and 
all 3 forms of p53. 
 
Expression of R273H Causes Induction of CTGF Expression 
 Previous studies have shown that the interactions between MUC1 and p53 
modulate the expression of MMP1 and CTGF by binding upstream promoter elements 
[77, 100].  To examine whether the mutational status of p53 influenced the expression of 
these genes, we treated Colo357.ip53 cells with no doxycycline, 300 ng/ml, or 1000 
ng/ml to induce expression of wildtype, R175H, or 273H p53 respectively in each cell 
line.  RNA was isolated and expression of MMP1 and CTGF was evaluated by qRT-PCR 
(Figure 6.4).  Expression of p53 was also confirmed by two independent primer sets.  
Induction of p53 was dose dependent and similar for each cell line as compared to their 
untreated parental counterpart. MMP1 did not show substantial changes in expression, 
though at 300 ng/ml both wildtype and R175H expression caused a modest reduction in 
expression.  This was abrogated at 1000 ng/ml suggesting potential dose dependent 
effects.  By comparison, CTGF expression was significantly induced by R273H 
expression in a dose dependent manner.  Wildtype and R175H p53 also showed modest 
increases in CTGF, however, this was significantly less than R273H and only high dose 
wildtype p53 reached statistical significance (p=0.048), suggesting R273H preferentially 
induces CTGF expression. 
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Mutant p53 is Less Responsive to DNA Damage 
 We performed methylene blue based proliferation assays to determine if different 
p53 mutants influenced the growth of pancreatic tumor cells.  Cells received either no 
treatment or 1 µg/ml doxycycline refreshed daily for 1 week.  Interestingly, under steady 
state conditions we observed no significant impact of p53 expression on cellular growth.  
This was true even for expression of wildtype p53 (Figure 6.5A-D).  Under normal 
cellular conditions, p53 often does not exert any effect on cellular growth until the cell is 
stressed [208].  To test whether cells expressing p53 would respond differently in 
response to stress conditions, we performed cell proliferation assays with 10 Gray 
irradiation of the cells at 48 hours, and compared these results to our non-irradiated 
controls.  We found that irradiation decreased growth in all 3 cell lines as compared to 
non-irradiated controls; however, both R175H and R273H cells maintained growth near 
control levels until the 144 hour timepoint.  In contrast, cells expressing wildtype p53 
showed significantly decreased cellular growth at 120 hours (Figure 6.6A-C).  These 
results suggest that mutant p53 may be less responsive to induction of stress responses 
in these cells. 
 To further investigate this hypothesis, we performed western blot analysis to 
examine the induction of the stress response following DNA damage.  Cells either 
received no doxycycline or 1 µg/ml doxycycline with increasing doses of radiation.  All 3 
cell lines showed similar response profiles for phosphorylation of Chk1 and Chk2.  
However, western blot analysis for phosphorylation of p53 at Serine 15, a residue 
involved in stabilization and transcriptional activity, showed that only wildtype p53 was 
phosphorylated at this residue (Figure 6.7).  Cells that did not receive doxycycline 
showed no induction of p53, confirming that the phosphorylated p53 we observed was 
derived from the inducible recombinant construct.  Additionally, at 20 Gray irradiation, 
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wildtype p53 cells showed induction of the pro-apoptotic protein PUMA.  This induction 
was not observed in mutant p53 expressing cells.  This difference appears to be specific 
to irradiation, as UV damage was capable of inducing phosphorylation of all 3 p53 forms,  




 The interaction between MUC1 and p53 has been confirmed by a number of 
independent studies [77, 80].  Interestingly, these studies show that MUC1 and p53 co-
occupy promoters that are not regulated by p53 under normal circumstances.  While 
previous studies have shown that phosphorylation of the MUC1 cytoplasmic tail is an 
important regulatory step of this interaction, no studies have evaluated the impact of p53 
mutational status.  As p53 is mutated in a significant fraction of pancreatic tumors, 
mutation of p53 could significantly impact the outcome of these interactions [310]. We 
evaluated how mutations impacted this interaction using wildtype, R175H, and R273H 
mutants of p53.  We found that the R273H mutant preferentially interacted with MUC1; 
however, MUC1 showed interaction with all 3 p53 forms.  Several studies have shown 
that different p53 mutants can exhibit different gain-of-function effects within cancer 
[235, 316].   The differential interactions suggest that MUC1 may play a role in the 
regulation of these gain-of-function effects in pancreatic cancer.  Indeed, previous 
studies showing that MUC1 and p53 can alter the expression of CTGF and MMP1 were 
performed using S2013 cells that carry the R273H mutation [77, 100].  Our studies 
support a role for the R273H mutation in regulation of CTGF expression, as only our 
inducible R273H cell line was capable of significantly inducing expression of CTGF.  
Interestingly both wildtype and R175H p53 affected MMP1 expression with low dose 
induction; however, this effect was abrogated with higher dose expression.   This 
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suggests that p53 mutants may also exhibit dose dependent effects on certain 
promoters.  As mutant p53 is significantly more stable than wildtype p53, some gain-of-
function effects may be a result of changes of overall protein concentration in these dose 
dependent experiments. 
 The fact that MUC1 is also capable of interacting with wildtype p53 suggests that 
this interaction contributes to normal cellular responses.  In normal tissues MUC1 is 
spatially segregated from many receptor tyrosine kinases that can phosphorylate the 
cytoplasmic tail [26].  Similarly, p53 expression is normally tightly regulated and 
expressed at extremely low levels under unstressed conditions [208, 223].  However, 
during mechanical injury, the barriers that normally separate MUC1 and RTKs can be 
removed, allowing the two molecules to interact and engage in signaling.  Cellular stress 
also causes induction and stabilization of p53.  As such, it is possible that the interaction 
of MUC1 and p53 may represent a critical mediator of the response to cellular injury, 
helping the cell to make a decision about whether to live or die.  Cancer cells may co-opt 
this mechanism and use it to survive stresses such as loss of polarity through 
constitutive signaling through the MUC1 cytoplasmic tail.  
 Interestingly, under steady state conditions expression of p53 had no impact on 
the growth of Colo357 cells.  The fact that Colo357 also lacks detectable expression of 
endogenous p53 suggests that these cells may have become largely insensitive to p53 
expression.  Irradiating cells resulted in cellular death and appropriate phosphorylation of 
wildtype p53, suggesting that under stressed conditions p53 may still exert functional 
effects in these cells.  Furthermore, cells expressing wildtype p53 exhibited an earlier 
decrease in proliferation in response to irradiation and induction of the pro-apoptotic 
protein PUMA.  These effects were diminished in both mutants suggesting that these 
variants confer resistance to irradiation induced cell death by delaying or abrogating 
induction of apoptotic proteins.  Several studies have shown that mutants of p53 often 
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fail to induce expression of the apoptotic protein Bax [242].  The interaction of MUC1 
with p53 also preferentially blocks induction of Bax suggesting another means by which 
this signaling axis delays or inhibits apoptosis [80]. 
 Future studies examining gain-of-function effects of these mutants at promoter 
elements will provide further insight into how MUC1 regulates the transcriptional 
machinery of tumor cells.  While we have observed differential interaction between 
MUC1 and a few hotspot mutants of p53, design of additional mutants using the 
hotspots at G245, R248, R249, and R282 could provide further insight into the molecular 
mechanisms and effects of these interactions. Interestingly, preliminary data in our lab 
suggest that MUC1 interacts with p53 through its regulatory domain, whereas the 
hotspot mutations all reside within the DNA binding domain.  This may explain why 
MUC1 is capable of interacting with all 3 of our p53 species; however, mutation may 
result in structural changes that alter the affinity of this interaction.  In vitro biochemical 
assays of interaction may allow us to better understand these dynamics and remains an 
important area of future investigation.  
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Figure 6.1:  Expression of MUC1 and p53 in Pancreatic Cancer Cell Lines 
Western blot analysis screening expression of MUC1 and p53 in the pancreatic cell lines 
Panc1, S2013, and Colo357.  Both Panc1 and S2013 cells lack endogenous MUC1 
expression, requiring exogenous transfection to study MUC1.  Furthermore, these cell 
lines express the R273H mutant of p53 at detectable levels making them unsuitable for 
our system.  Colo357 cells represented the best combination of high endogenous MUC1 





































































Figure 6.2:  Characterization of a Dox-Inducible p53 Expression System 
We chose to study 2 hotspot mutants (R175H and R273H), as well as wildtype p53.  A 
general schematic (A) of the expressed protein is provided highlighting functional 
domains, the site of mutation (star), and the attachment of a 3X Flag sequence for 
detection.  B) Generation of specific site mutations was confirmed by sequencing and a 
chromatogram of the results is presented.  The R175H and R273H mutant codons are 
highlighted in red.  C) Inducible expression of p53 was confirmed by western blot 
analysis for both p53 (DO-1) and the Flag tag (M2).  Increasing concentrations of 
doxycycline resulted in a dose dependent induction of p53 in all 3 cell lines.  β-actin was 
used as a loading control.  Consistent induction was confirmed by multiple replications of 
the dose curve. 
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Figure 6.3:  MUC1 Preferentially Interacts with the R273H Mutant 
Evaluation of the effects of mutation of p53 on interactions with MUC1: reciprocal co-
immunoprecipitation assays.  A) Western blot analysis of input samples confirming equal 
concentrations of proteins were used for immunoprecipitation in all 3 cell lines.  B) 
Immunoprecipitation of p53 using M2 (anti-FLAG) agarose beads and western blot 
analysis of p53 and MUC1 shows slightly increased levels of MUC1 pulldown in the 
R273H lane; however, this interpretation is complicated by light chain reactivity detected 
by the secondary antibody, as seen in the IgG control lane.  C) Immunoprecipitation of 
MUC1 shows increased co-immunoprecipitated R273H p53, as compared to wildtype 
and R175H p53.  IgG lanes confirm that the interaction is specific.  Co-
























Figure 6.4:  R273H Preferentially Induces CTGF Expression 
qRT-PCR analysis of p53, MMP1, and CTGF mRNA expression in Colo357.WTp53, 
R175H, and R273H cell lines.  Expression of each gene was normalized to the untreated 
parental control.  Induction of p53 was shown to be dose dependent and similar 
induction is observed for all 3 cell lines.  MMP1 expression showed modest decrease 
with low dose expression of wildtype or R175H p53.  This was abrogated with high dose 
expression.  All 3 p53 forms promoted some induction of CTGF, however only R273H 
promoted a significant increase in CTGF expression in a dose dependent manner.  At 
high doses of Dox, expression of wildtype p53 induced CTGF above statistical threshold 
(p=0.048).  Statistics were performed using two-tailed student’s t-test comparing the 
doxycycline treated lines to the untreated parental control.  Each sample was performed 
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Figure 6.5:  Expression of p53 Does Not Impact Steady State Growth 
Methylene blue assays measuring proliferation of all 3 p53 cell lines in the presence or 
absence of 1 µg/ml doxycycline.  Results are presented as the average absorbance at 
650 nm.  Expression of wildtype (A), R175H (B), or R273H (C) showed no significant 
impact on growth as compared to the non-dox control cells.  A comparison of all 3 lines 
(D) shows that the form of p53 has no impact on steady state growth.  Statistical 
analysis was performed using 2-way ANOVA.  Absorbance represents an average of 6 
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Figure 6.6:  Mutant p53 Delays the Onset of Radiation Induced Growth Inhibition 
Methylene blue proliferation assays measuring cellular growth of p53 cell lines with or 
without 10 Gray irradiation at 48 hours. Results are presented as the average 
absorbance at 650 nm.  With irradiation all cell lines showed slowed growth and showed 
loss of proliferation at 144 hours.  However, both R175H (B) and R273H (C) maintained 
near control level growth until 144 hours, whereas wildtype p53 growth decreased 24 
hours earlier (A).  Statistical analysis was performed using 2-way ANOVA. Absorbance 
represents an average of 6 independent wells to control for variability in plating, growth 
due to plate position, and irradiation exposure. 
  

























































































Figure 6.7:  Mutation of p53 Alters Activation of DNA Damage Response 
Colo357. WT p53 (A), R175H p53 (B), or R273H p53 (C) were treated with increasing 
doses of radiation in the presence or absence of 1 µg/ml doxycycline.  1 hour post-
irradiation cells were lysed and examined by western blotting for induction of stress 
related signals phosphoChk1, phosphoChk2, phosphoSer15-p53, as well as expression 
of p21 and PUMA.  All 3 lines showed similar profiles for phosphorylation of Chk1 and 
Chk2.  However, only wildtype p53 showed phosphorylation at Serine 15 and induction 
of PUMA expression.  Western blots are representative images of multiple experiments. 
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Figure 6.8:  R175H p53 Exhibits Altered Response to UV Damage 
Colo357. WT, R175H, R273H, and control cells were exposed to UV irradiation to induce 
DNA damage.  1 hour post UV exposure, cells were lysed and examined for 
phosphorylation of p53 and p21 expression by western blotting.  UV damage induced 
phosphorylation of all 3 mutants, however, R175H showed diminished activity.  Loss of 
p21 expression indicates cells had initiated the apoptotic response.  Western blots are 
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Chapter VII: Summary and Future Directions 
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7.  Summary 
	
 The role of transmembrane mucins in the progression of cancer is well 
established and the knowledge of their signaling capacity continues to grow [75, 81, 86, 
87, 102, 268, 320, 321].  MUC1 remains the most studied of these mucins.  The capacity 
of MUC1 to alter the activity of different signaling cascades under different contexts has 
been demonstrated; however, the manner and extent to which MUC1 integrates multiple 
signals has not been well-characterized.  We have demonstrated that the C-terminal 
subunit of MUC1 exists in a wide array of modified states, including numerous distinct 
phosphorylated forms, suggesting that MUC1 integrates several signals concurrently to 
affect multiple signaling and biological pathways within the cell.  Furthermore, changes 
in biological conditions of the cell result in broad alterations in signaling and 
transcriptional regulation, lending support to the hypothesis that MUC1 acts as a sensor 
of the surrounding environmental conditions and commensurate modifier of cell activity 
[19, 26].  Interestingly, specific MUC1 splice variants also appear to exist in extensively 
modified states, suggesting additional means of regulating signaling pathways by 
altering the N-terminal portion of MUC1 exposed to the extracellular space.  Expression 
of truncated glycans has also been shown to modulate the tumorigenic properties of 
mucins, suggesting that while the C-terminus is engaged in signaling, the N-terminal 
extracellular domain may play a significant role in the detection of the surroundings to 
initiate or modify those signals [42, 73, 322, 323].   
 While several studies have shown the impact of MUC1 on downstream signaling 
cascades such as ERK, few studies have evaluated the corresponding impact on 
transcriptional activity downstream of these effectors [81, 86].  We found that expression 
of MUC1 promoted shifts in the composition of the dimeric transcription factor AP-1 to 
favor c-Jun:FRA-1 dimers, seemingly due to induction of upstream ERK activity.  As the 
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composition of AP-1 has been shown to influence the DNA binding properties of the 
transcription factor, this suggests that MUC1 can reprogram gene expression by altering 
the formation of specific transcriptional complexes [196-198].  As many transcription 
factors are rapidly stabilized or degraded in response to post-translational modification, 
the integration of extracellular signals through MUC1 may represent a critical regulatory 
step of gene expression in response to changes in the environment.  In our studies, 
MUC1 expression resulted in increased expression of known targets of FRA-1 involved 
in epithelial-to-mesenchymal transition.  Preliminary studies also suggest that MUC1 
expression increases occupancy of FRA-1 at these sites.  Different stimuli may induce 
differential downstream impact on transcriptional complexes, altering the gene 
expression profiles accordingly.  This may explain in part how MUC1 impacts numerous 
pathways under different cellular contexts [87, 169, 274, 321, 324]. 
Interestingly, expression of FRA-1 itself also appears to play a role in pancreatic 
tumor progression.  Orthotopic tumor models demonstrated that knockdown of FRA-1 
decreases tumor growth.  These studies represent the first evidence for FRA-1 playing 
an in vivo role in the progression of pancreatic cancer, which provides support for 
previous in vitro evidence [289].  Gene and protein expression analysis of human PDAC 
samples further suggests elevation of FRA-1 expression in PDAC.  While we did not 
observe significant correlations between FRA-1 and protein levels of EMT targets, future 
studies utilizing more quantitative measures may allow for better models to study the 
correlations between these proteins.  Stratification of pancreatic cancer samples into 
distinct subtypes may also provide clarity for these comparisons.  Furthermore, in vitro 
studies suggest that targeting FRA-1 may represent a viable option to decrease tumor 
growth.  While our studies did not demonstrate synergy between FRA-1 knockdown and 
BETi, several other methods of targeting AP-1 dimers exist including DNA aptamers and 
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specific AP-1 inhibitors and future studies may provide better insight into the targeting of 
FRA-1 [309].     
While the impact of MUC1 on the formation of AP-1 appears to involve upstream 
signaling cascades, MUC1 has been shown to regulate the function of p53 through 
direct binding [77, 80].  Interestingly, this results in changes to promoter occupancy of 
complexes containing both p53 and MUC1.  Mutation of p53 is extremely common in 
pancreatic cancer and is often accompanied by gain-of-function effects, including 
alterations to DNA binding capacity [235, 237, 314]. Our use of inducible models of p53 
expression showed that MUC1 preferentially associates with the R273H p53 mutant as 
opposed to wildtype or R175H p53.  This p53 mutant appears to exert specific gain-of-
function control at the CTGF locus, as expression of R273H in Colo357 cells can induce 
expression of CTGF, whereas wildtype and R175H show relatively little induction.  
Studies showing that MUC1 can regulate expression of CTGF have primarily been 
performed using cell lines expressing the R273H p53 mutant, supporting the hypothesis 
that MUC1 may preferentially exert gain of function effects with this mutant [100].  
Interestingly, mutant p53 often binds DNA in a structure specific manner, suggesting that 
mapping regions of predicted alternative DNA structures may provide insight into both 
p53 and MUC1 binding in cancer.  Studies correlating specific p53 to patient outcomes 
may also help to identify p53 mutants that drive distinct gain-of-function effects within 
pancreatic cancer. 
While these studies have provided significant insight into biological roles of 
MUC1 in gene regulation, induction of signaling cascades, regulation of transcriptional 
complexes, and overall tumor progression, they remain limited through our lack of 
quantitative understanding of the mechanism.  Indeed, while MUC1 is known to drive 
downstream signaling cascades, the rate at which this occurs and the magnitiude of the 
effect is not known.  This limits the predictive power of our model systems and hampers 
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efforts to effectively target MUC1 and downstream effectors.  Future studies using more 
quantitative models, such as the CRISPR based systems, single cell imaging, super 
resolution microscopy, and real-time tracking will allow us to better define the molecular 
circuits involved in MUC1 signaling.  The expansion of human samples available for 
study through the UNMC Rapid Autopsy Program and Next Gen Sequencing datasets of 
these samples will further allow for deep quantitative analyses allowing for better 
understanding of the human condition and correlation of these models with in vitro 
models.  Expansion of studies from the biological systems into the computational 
systems will allow for greater understanding of the complexities of pancreatic cancer and 
offer many tools for the future study of pancreatic cancer. 
 
7.1 Evaluate the Impact of MUC1 on the Global Promoter Occupancy 
of p53, c-Jun, and FRA-1 
 We have shown that expression of MUC1 influences the formation of AP-1 to 
favor c-Jun:FRA-1 dimers.  Previous studies have shown that MUC1 displaces c-Jun 
from both the MMP1 and CTGF promoters [77, 100].  No studies have evaluated how 
MUC1 impacts the occupancy of these factors on a global scale.  To address this 
question, we have initiated experiments to isolate chromatin from MUC1 overexpressing 
cells and their parental counterparts to perform ChIP-seq for c-Jun and FRA-1.  Co-
occupancy of c-Jun and FRA-1 at promoter elements will be confirmed using ChIP-
reChIP assays. Preliminary studies performing ChIP followed by qRT-PCR of select 
sites showed changes in promoter occupancy of several FRA-1:EMT genes; however, 
these preliminary studies need to be repeated and further optimized (Figure 7.1).  These 
studies will be paired with RNA-seq analysis of the cell lines to identify genes that are 
differentially regulated due to changes in promoter occupancy.  To date we have  
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performed RNA-seq analysis of S2013.Neo and MIF cells, as well as FRA-1 
overexpression and knockdown lines (Figure 7.2A).  The differences in gene regulation 
by FRA-1 between the S2013.Neo and MIF cells further support differences in global 
DNA binding (Figure 7.2B).  
The previous studies showing displacement of c-Jun from promoter elements 
also highlighted increased occupancy of MUC1 and p53 at these sites [77, 100].  We 
wish to examine how the mutational status of p53 influences its binding capacity at these 
sites and others within the genome.  Recent studies of p53 have shown that different 
mutants of p53 retain different DNA binding properties [235, 236, 313, 314].  We have 
shown that MUC1 preferentially interacts with the R273H hotspot mutant.  Our qRT-PCR 
data also suggests that different p53 mutants exhibit differential regulation of these gene 
targets.  We hypothesize that MUC1 may regulate certain gain-of-function effects by 
regulating DNA binding depending on the mutant of p53 expressed.  As such, we intend 
to extend these studies to evaluate changes in p53 binding in conjunction with MUC1 
expression using our dox inducible models of p53. Using ChIP-seq we can assess 
whether different p53 mutants exhibit differential DNA binding with MUC1 expression. 
 
7.2 Assess the role of MUC1 in the temporal regulation of AP-1 
induction 
 Jun and Fos proteins are both immediate early genes and are rapidly induced in 
response to various stimuli [121].  While we demonstrated that MUC1 could readily alter 
the composition of the AP-1 dimer, we still don’t understand the stoichiometry and 
temporal dynamics of this process.  As different Jun and Fos proteins exhibit different 
kinetics, the rise and fall of these proteins likely regulates the relative composition of AP-
1 over time.  The expression of particular dimers may also be critical for the appropriate 
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regulation of downstream gene targets over time.  Furthermore, as MUC1 relays 
information from the surrounding microenvironment, any changes in the surroundings 
may result in a different temporal response if MUC1 is present or absent. 
 To study the levels of AP-1 proteins in real time, we are currently designing a 
CRISPR based system that will allow for the generation of knock-in fluorescent Jun or 
Fos proteins whose expression and interactions can be followed by fluorescence assays 
and by Fluorescence Resonance Energy Transfer (FRET).  This system is being 
modeled on previous work by Dr. John Albeck, and he has generously provided initial 
constructs that are being used as a framework for our studies [325].  These constructs 
consist of homologous arms to c-Jun or FRA-1 as well as an in-frame cDNA sequence 
for a fluorescent protein (Figure 7.3).  These constructs are paired with a CRISPR 
construct containing a specific sgRNA against genomic sequences within FRA-1 or c-
Jun.  After transfection, cells are sorted for fluorescence that should only be present in 
cells that have undergone appropriate genomic editing.  Initial pilot experiments have 
shown modest efficacy (Figure 7.4).  However, the number of positive cells has been 
insufficient for experimentation to date.  In order to increase efficiency of targeting, we 
have moved to use lentiviral transduction of CRISPR constructs and mutation of specific 
PAM sequences to eliminate non-specific cutting. 
 As a secondary approach, we are generating fusion protein constructs for AP-1 
proteins should the CRISPR approach prove to be too difficult with the available 
facilities.  These constructs will allow us to study stabilization of AP-1 proteins in 
response to post-translational modification, however, we will not be able to evaluate 
responses that lead to increased AP-1 gene expression as these constructs won’t have 
the endogenous genomic promoter elements and enhancers.   
 If our experimental system is successful, the response of AP-1 proteins will be 
measured in real-time using live fluorescent microscopy of cells.  How different stimuli 
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influence responsiveness will be assessed by multi-well assays in which cells are treated 
with various growth factors, drugs, or other stimuli in the presence or absence of MUC1 
expression.  Fluorescence intensity will be tracked over time and used as readout of AP-
1 protein levels and confirmed using time-course studies based on the real-time imaging 
results. 
 
7.3 Stratification of Rapid Autopsy Specimens by Molecular Subtype 
 In recent years, several studies have explored the diversity of pancreatic cancer 
and categorized tumors on the basis of genomic, transcriptomic, and epigenomic 
features [16-18].  Due to the robust stromal involvement in pancreatic cancer, these 
studies remain controversial, as the molecular characteristics are often complicated 
through the inclusion of non-tumor cells in the analysis.  Within UNMC, we have access 
to a substantial number (~100) of pancreatic tumor specimens through the UNMC Rapid 
Autopsy Program (RAP).  We will attempt to validate these subtypes through clustering 
analysis of gene expression in these tumors.  While previous studies have primarily used 
RNA-seq to measure gene expression, this is a costly approach.  In collaboration with 
Dr. Fang Yu of the UNMC Biostatistics Department, we are incorporating transcriptome 
data from the recent manuscripts to identify the most differentially regulated genes and 
generate a smaller subset of genes to evaluate as biomarkers of biological subsets of 
pancreatic cancer (Figure 7.5). 
 To test this gene set, we will perform hierarchical clustering based on Euclidean 
distance using previously published work from other groups to assess how well this 
signature can recapitulate the subtypes previously identified (Figure 7.6).  As these 
subtypes remain controversial, we will attempt to incorporate findings from multiple 
studies to avoid overfitting the data or biasing our results to one paradigm or another.  
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Once we have chosen a biomarker gene profile, we will perform digital PCR on RAP 
samples using Nanostring technology to generate our expression profile.  This 
technology has the benefit of being more cost-effective than RNA-seq and requiring 
lower RNA quality, which is easier to achieve with stored RAP specimens.  We will then 
perform unsupervised clustering of our gene expression and identify the number of 
subtypes observed and compare them to previously published subtypes.  These 
stratified groups can then be used for further analyses examining survival, treatment 
response, metastatic spread, and correlation with protein expression. 
 
7.4 Evaluate the Biochemical Properties of the MUC1:p53 Interaction 
and Expand Gain-of-Function Studies of Mutant p53. 
 The interaction of MUC1 and p53 is postulated to involve the regulatory domain 
of p53, however, this does not explain why we observe differences in the interaction with 
mutations occurring within the DNA binding domain of p53 [80].  In order to effectively 
function as a transcription factor, p53 must oligomerize to form a tetramer.  Previous 
studies in the lab have suggested that MUC1 may modulate the ability to form these 
oligomeric complexes, however, these studies remain unconfirmed.   In collaboration 
with Edwin Wiest, we have focused on purifying recombinant MUC1 and p53 (Figure 
7.7).  The interactions between these two proteins will then be assessed by biochemical 
assays including Isothermal Titration Calorimetry (ITC).  We will further explore the 
impact of mutation through the generation of specific p53 mutants, including the R175H 
and R273H mutants previously studied. 
 We would also like to further expand our studies to include additional hotspot 
mutants at G245, R248, R249, and R282.  These mutants will be generated in our Dox 
inducible system and validated using the same approaches used for R175H and R273H.  
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As p53 can also utilize internal start sites and splice sites, we would like to additionally 
generate inducible constructs of these variants.  We have already generated the Δ40p53 
variant (Figure 7.8).  As these proteins exhibit different transcriptional and regulatory 
dynamics, they may further influence the gain-of-function effects observed within cancer.  
There has also been no exploration of whether these variants are capable of interacting 
with MUC1.  To evaluate the putative roles mediated by association of MUC1 and p53, 
and those driven by p53 alone, we intend to expand these studies to include shRNA-
mediated knockdown or CRISPR knockout of MUC1.   
 
7.5 Evaluation of FRA-1 Expression and its Role in Early Pancreatic 
Cancer Development 
 In cancer, deregulation of immediate early gene products, such as c-Myc, is 
extremely common [326].  Expression of these genes is often rapidly induced in 
response to oncogene expression, typically as a result of post-translational stabilization 
due to constitutive signaling.  As a result, many of these genes play a critical role in the 
development and progression of early tumors.  In pancreatic cancer, mutation of Kras is 
the most common driver of tumor development [13].  Several studies have shown that 
the pro-oncogenic activity of AP-1 proteins, like c-Jun and FRA-1 relies on co-expression 
of an oncogenic driver like Kras [287, 301, 327].  We found that expression of FRA-1 
promoted increased invasive behavior and knockdown of FRA-1 decreases tumor 
growth.  Furthermore, while we found that tumors typically exhibited increased 
expression of FRA-1, the stage at which this occurs remains unknown. 
 To evaluate expression of FRA-1 in early tumor development, we will perform 
immunohistochemistry for FRA-1 using PanIN confirmed slides.  In preliminary studies, 
we found that FRA-1 expression does not substantially increase until PanIN-3 (Figure 
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7.9).  This is despite the presence of Ras mutations in earlier PanIN lesions, suggesting 
that additional regulatory changes must occur before FRA-1 is stabilized.  Interestingly, 
expression of miR-34 is lost in later stages of development (PanIN-3 to PDAC) [328].  
Expression of miR-34 has been shown to inhibit expression of FRA-1 and is normally 
regulated by p53, suggesting that loss of p53 and miR-34 may be critical events for 
induction of FRA-1 [329, 330].  Further immunohistochemistry with expanded samples 
will help to confirm the stage at which FRA-1 expression increases.  Pairing these 
studies with expression of p53 and miR-34 will further elucidate the genomic alterations 
critical for FRA-1 induction. 
 In long-term studies, it would be of interest to cross FOSL1 floxed mice into the 
KC and KPC mouse models of pancreatic cancer.  These studies would tease out the 
importance of FRA-1 expression in the formation and progression of pancreatic cancer.  
Furthermore, comparing the results from KC and KPC mice may allow for the 
determination of the importance of p53 in these effects.  Unfortunately, the FOSL1 floxed 




Figure 7.1:  MUC1 Expression Alters Occupancy of FRA-1 at EMT Gene Promoters 
FRA-1 bound chromatin was immunoprecipitated from S2013.Neo and MIF cells and 
analyzed for promoter occupancy by qRT-PCR.  Known sites of promoter binding were 
used for AXL, FN1, SNAI2, and TGFB2, and normalized to IgG and Input controls.  
MUC1 expression resulted in increased occupancy at genes involved in EMT (AXL, FN1, 

































Figure 7.2:  Differential Expression of Select Genes in S2013.Neo and MIF Lines 
A) Table of differentially regulated genes between S2013.Neo and MIF cells.  Genes on 
the left are upregulated (green arrow) in MIF cells.  Genes on right (red arrow) are down 
regulated in MIF cells.  B) Venn diagrams highlighting the differential regulation of FRA-1 
targets in S2013.Neo and MIF cells.  MIF cells show higher numbers of unique targets 
as compared to Neo cells suggesting changes to FRA-1 function between the lines.   
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Figure 7.3:  Vector Maps of Homologous Constructs for AP-1 CRISPR 
Vector map showing the design of homologous arm constructs for the generation of 
FRA-1 and c-Jun fluorescent protein fusions using CRISPR.  Homologous arms are 
approximately 1.5kb sequences up or downstream of CRISPR cut site.  Fluorescent 





Figure 7.4:  Validation of CRISPR Constructs 
CRISPR constructs targeting either FRA-1 or c-Jun were transfected into S2013 or 293A 
cells with homologous donor constructs.  Cells were assessed for expression of 
fluorescent fusion products by confocal microscopy.  A small number of red (FRA1) and 






Figure 7.5:  Differential Expression of Genes Between PDAC Subtypes 
Using previously published expression data from the PDAC subtype manuscript by 
Bailey, et al [18], and box plots for each of the approximately 18,000 genes examined 
were generated using R-programming language.  Statistical analysis of differential gene 
expression was performed using both SAM and LIMMA methods.  Genes that were 



























































































Figure 7.6:  Hierarchical Clustering of Tumors by Gene Expression Profile 
Gene expression profiles were identified from Bailey, et. al [18] manuscript of pancreatic 
cancer subtypes.  These profiles were than used to perform hierarchical clustering 
based upon Euclidean distance to determine how many genes were required to 
recapitulate the original findings.   
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Figure 7.7:  Purification of Recombinant MUC1 
E. Coli optimized cDNA sequence for MUC1 was cloned into the pGEX.4T1 expression 
vector to generate recombinant GST-tagged MUC1.  These constructs were transfected 
into C41 or C43 bacterial cells and recombinant MUC1 isolated using a GST column.  
Purification was confirmed by western blot analysis of elution fractions (E1-E6). 
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Figure 7.8:  Expression of Dox-Inducible p53 Truncated Mutants 
A) Schematic of additional p53 constructs designed.  Tagless p53 lacks the 3X Flag 
sequence.  FL-p53 should only express full-length p53, whereas Δ40p53 should express 
N-terminally truncated p53 lacking the first 40 amino acids.  B) Mutations of methionine 
to valine were introduced into the p53 sequence to generate FL p53 and Δ40p53.  DO-1 
epitope is highlighted to show that Δ40p53 is not detectable with this antibody.  C) 
Inducible expression of these constructs was measured with 1 µg/ml doxycycline and 
western blot analysis for both p53 (DO-1) and the Flag tag.  Overlay of these two signals 
highlights FL-p53 in yellow, whereas tagless is absent by Flag and Δ40p53 is absent by 
DO-1. Interestingly, FL p53 induces a predicted full-length size as well as another 
truncated form smaller than Δ40p53, suggesting utilization of another internal start site at 
amino acid 133 or 160.  These studies suggest that for full design of the system, these 
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Figure 7.9:  Expression of FRA-1 in PanIN Lesions 
Immunohistochemistry was performed on PanIN lesion slides to assess expression of 
FRA-1.  3 separate slides were used for each lesion (PanIN-1 through 3).  
Representative images for each stage are shown (PanIN-1 through PDAC).  Heatmaps 
showing the relative expression are presented showing that FRA-1 is only modestly 
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